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The development of tissue engineering as a new promising discipline for the 
repair of various defects and injuries is primarily connected with the production of new 
tissues or whole organs in vitro. In the preparation of new tissue prosthetics it is crucial 
to use an appropriate scaffold as a carrier of different kinds of new cells. Highly-porous 
scaffolds with interconnected pores are favoured in tissue-engineering applications 
(Sato T. et al., 2004). Biodegradable nanofibers produced by electrospinning are 
receiving much attention nowadays. These scaffolds contain fibers in the diameter of 
the extracellular matrix (ECM; Khil M.S., et al., 2005), which plays a pivotal role in cell 
adhesion, proliferation, migration and differentiation (Khil M.S. et al., 2011). The 
optimal scaffold in tissue engineering should mimic the natural ECM and thus provide 
an appropriate microenvironment for the cells of new formed tissues. The big 
advantages in using nanofibers as a scaffold for tissue regeneration are found in their 
topographical features, which can be easily adjusted to fit specific applications (Lukas 
D. et al., 2009; Bhardwaj N. and Kundu S.C., 2010; Grafahrend D. et al., 2011).  
More than a hundred surgical meshes have been designed for use in abdominal 
wall hernia repair procedures (Shankaran V. et al., 2011). However, no single mesh 
has yet demonstrated the ability to simultaneously promote host tissue remodelling 
and the high-strength repair of abdominal wall defects (Ebersole G.C et al., 2012). The 
ideal mesh does not yet exist, and still needs to be developed. One of the possibilities 
on how to effectively improve the properties of the surgical meshes for incisional hernia 
repair that has been used till now is to combine them with other promising tissue 
engineered scaffolds, or to completely replace the meshes through them.  
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1.1 Hernia in general 
An abdominal hernia is an abnormal protrusion of the intra-abdominal contents 
through a defect in the abdominal wall. This defect may occur either as an indirect 
hernia that is congenital or a direct hernia that is acquired. Abdominal wall hernias are 
very common. Approximately 50,000 hernioplasties are performed each year in 
Germany alone (Bittner R. et al., 2014) and 100,000-200,000 incisional hernia repairs 
are performed annually in the United States (Flum D.R. et al., 2003). Operations for 
abdominal wall hernia are important from the medical and socio-economical 
perspective because of their high frequency, especially in the elderly, and the potential 






Figure 1. Abdominal wall hernia. The circumference of the bowel and progressive situation. (A) 
partial involvement of the bowel circumference without obstruction. (B) Subacute obstruction. (C) 
Complete obstruction and strangulation. 
Notes: Adapted from Bay-Nielsen M., 2013. 
Complications of abdominal wall hernias can lead to incarceration with a 
subsequent acute obstruction and strangulation, which even could cause a life 
threatening situation (Figure 1). Incarceration is the state when an external hernia 
cannot be reduced into the abdomen. Incarceration is caused by (a) a tight hernia sac 
neck; (b) adhesion between the hernia contents and the sac lining, with the possible 
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development of previous ischemia and inflammation; (c) development of pathology in 
the incarcerated viscus, e.g. a carcinoma or diverticulitis in the incarcerated colon; (d) 
the impaction of faeces in an incarcerated colon (Bay-Nielsen M., 2013). 
1.1.1 Types of hernias 
Abdominal wall hernias are classified as external either when the hernia sac is 
clinically palpable or occult external due to the presence of ansa within the abdominal 
wall, which do not emerge on the surface (Fisch A.E. and Brodey P.A., 1981). It could 
be congenital or acquired through trauma or after surgery. Abdominal wall hernias are 
considered the most frequent external hernias (Lee G.H. and Cohen A.J., 1993; Miller 
P.A. et al., 1995). 
Inguinal hernia could be classified as an oblique external (indirect) hernia or a 
direct hernia. Both of them occur due to the acquired weakness and dilatation of the 
internal inguinal ring. Inguinal hernias are more prevalent in males. An indirect hernia 
is localized laterally to the inferior epigastric vessels whereas a direct hernia is 
localized medially (Ekberg O. and Kesek P., 1987). 
Femoral hernias are rare in comparison with inguinal hernias. They are more 
common in women between 30 and 60 years of age who have been pregnant or are 
obese, but they can also arise in men. They usually occur on the right side (Ianora 
A.A., 2000).  
Ventral hernias, also called primary abdominal wall hernias, include all hernias 
localized in the anterior abdominal wall except for inguinal hernias (Harrison L.A. et al., 
1995). 
Umbilical hernia is a very common type of ventral hernia. This hernia represents 
a protrusion through the linea alba in the region of the umbilicus. Umbilical hernias are 
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most common in females (Lee G.H. and Cohen A.J., 1993). Frequent risk factors are 
obesity, multiple pregnancies and ascites (Miller P.A. et al., 1995).  
Epigastric hernias are less common and can develop in both women and men. 
It occurs along the xipho-umbilical line through the stretching of the linea alba and 
usually develops in people born with a weak spot in the abdominal muscle (Miller P.A. 
et al., 1995).  
Spigelian hernias are truly rare and occur in less than 2% of patients with any 
anterior abdominal wall hernias (Hiller N. et al., 1994). They are generally acquired 
lateral to the rectus muscle and below the umbilicus.  
Parastromal hernias are caused by the protrusion of a bowel ansa near an 
ileostomy or a colostomy (Etherington R.J. et al., 1990; Lee G.H. and Cohen A.J., 
1993). Most of these hernias occur as a consequence of technical errors during 
surgery. Other risk factors are obesity, chronic coughing and a distended abdomen 
(Lee G.H. and Cohen A.J., 1993).  These types of hernias are excluded from the group 
of incisional abdominal wall hernias although they are by definition incisional hernias. 
Parastromal hernias are included in a different group requiring specific properties and 
treatments (Muysoms F.E. et al., 2009).  
The last main type of hernia is an incisional hernia. 
1.2 Incisional hernia 
For an incisional hernia there was the decision to use the definition proposed by 
Korenkov et al. An incisional hernia is: “Any abdominal wall gap with or without a bulge 
in the area of a postoperative scar perceptible or palpable by clinical examination or 
imaging” (Korenkov M. et al., 2001). 
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1.2.1 Classification of incisional abdominal wall hernia 
A general classification of incisional abdominal wall hernias is important for an 
objective comparison of publishing results and future hernia studies. It is necessary to 
know whether various medical cases described in different studies are comparable. 
Until 2009 there were suggested several classifications in the literature primarily for 
incisional hernias but the authors were uncertain for a long time. For example the 
classification proposed by Chervrel and Rath in 2000 was simple and the required data 
to match the classification were easily obtained (Chevrel J.P. and Rath A.M., 2000). 
Unfortunately, this classification has not been commonly used in the literature. Thus 
several members of the European Hernia Society suggested the current classification 







Figure 2. Classification of an incisional abdominal wall hernia according to localisation. (A) Five 
midline subgroups. (B) Four lateral subgroups.   
Notes: Adapted from Muysoms F.E. et al., 2009. 
 Muysoms et al. divide an incisional hernia according to main localisation into a 
midline and lateral group. The midline group is subsequently divided into 5 subgroups 
named M1- M5, moving from the xiphoid to the pubic bone (Figure 2A). The lateral 
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group is divided into 4 other groups named L1-L4, and is presented in Figure 2B 
(Muysoms F.E. et al., 2009).   
Complementary classification includes information about the size of a hernia 
when the weight and height is measured or it was accepted to use a semi-quantitative 
division, taking only the width as a measurement. The size of the hernia is then divided 
into 3 groups (W1  4 cm; W2 ≥ 4-10 cm; W3 ≥ 10 cm). The last parameter included 
the information if an incisional hernia is a recurrence and how many time after previous 
repair (Muysoms F.E. et al., 2009). 
1.2.2 Incidence of incisional hernia and the need for using prosthetic 
repair 
An incisional hernia is the most common postoperative complication, affecting up 
to 20% of patients after a midline incision and is associated with high morbidity and 
significant socio-economic costs (Sugerman H.J. et al., 1996; Hoer J. et al. 2002).  The 
treatment of incisional hernias using primary wound closure (simple suture) and fascia 
doubling in Mayo’s technique had a recurrence rate of more than 40% (Mayo W.J., 
1899; Paul A. et al., 1998). Progress in the knowledge of reinforcements of the 
abdominal wall using prosthetic meshes has reputedly reduced the rate up to 10% in 
relation to the type of hernia and the technique used (Conze J. et al., 2005). In contrast 
to this data there is the often cited randomised controlled trial study from Holland 
revealing the 10-year cumulative rate of recurrence after incisional hernia repair even 
at an unacceptable level of 63% for suture repair and 32% for prosthetic repair (Burger 
J.W. et al, 2004). In 2008 Cochrane’s review of 3 trial studies comparing open primary 
suture repair of incisional hernia and open prosthetic repair showed recurrence rates 
of 54% and 16%, respectively (den Hartog D. et al., 2008). The cumulative incidence 
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of re-operation after incisional hernia repair, with or without a surgical mesh, has 
exhibited a linear rise over the years. An implantation of a mesh did not reduce the risk 
of recurrence – it only delayed the onset of hernia recurrence by 2-3 years (Flum D.R. 
et al., 2003). 
Synthetic meshes have become a standard aspect of care in ventral and 
incisional hernia repair, even though the recurrence rates are still very high (Usher F.C. 
et al.,1958). Incorporating polymeric meshes during hernia repair has demonstrated 
the reduction of recurrence rates, minimizing of pain, improving patient outcomes 
postoperatively in general, and is not associated with the increased incidence of 
complication (Luijendijk R.W. et al., 2000; Burger J.W. et al, 2004).  
1.2.3 The basic operation technique in prosthetic incisional hernia 
repair 
Worldwide, there is insufficient coherence on the terminology for a prosthetic 
mesh position either during a laparoscopic or open approach to incisional hernia repair. 
Thus the European Hernia Society has attempted to unite the existing terminology and 
proposethe definition of positions listed in Table 1 and the illustration represented by 
Figure 3 (Muysoms F. et al., 2012).  
Another discussed topic related to ventral and incisional hernia repair techniques 
is the use of the laparoscopic approach. The laparoscopic repair of hernias was 
introduce in the 1990s with potential advantages such as the need for smaller incisions, 
a decrease in wound infection, less consumption of narcotics after surgeries and a 
shorter hospital stay (Park A. et al., 1998; Ramshaw B.J. et al., 1999). The 5-year 
recurrence rates of laparoscopic repair and open mesh repair are nearly the same, 
29% and 28%, respectively (Ballem N. et al., 2008). However, Ballem et al. also 
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revealed that patients who required conversion from laparoscopic to open repair had 
a higher rate of immunosuppression, ascites and a larger size defect. All these 
complications contributed to the 5year rate of recurrence at a level of up to 60% 
(Ballem N. et al., 2008). 
Table 1. Definitions of the mesh position in ventral and incisional hernia repair 








Figure 3. Terminology of mesh position in ventral and incisional hernia repair. 
Notes: Adapted from Muysoms F. et al., 2012 
Position Definition 
Onlay 
The mesh is positioned above the abdominal wall muscles and fascia, behind 
the subcutaneous fat 
Inlay 
The mesh is positioned in the hernia defect, without overlap, and fixed to the 
margins of the defect 
Retromuscular 
Medial 
The mesh is positioned behind the rectus abdominis muscle and in front of the 
posterior rectus fascia or in front of the peritoneum 
Retromuscular 
Lateral 
The mesh is placed in the plane between the lateral abdominal wall muscles 
Preperitoneal 
The mesh is placed in the plane behind all the abdominal wall muscles in front 
of the peritoneum 
Intraperitoneal 




1.2.4 The main risks of an incisional hernia developing after 
prosthetic repair 
Repairs to a large incisional defect often requires the use of a prosthetic implant, 
which can cause various long-term complications, e.g. adhesion formation, graft 
infection/rejection, erosions, migration, loss of bio-compliance, fistula formation and 
hernia recurrence (Vrijland W.W. et al., 2000; Jacob B.P. et al., 2007; Losanoff J.E. et 
al., 2002; Jezupovs A. and Mihelsons M., 2006; Jacob B.P. and Ramshaw B., 2013). 
Other studies have also revealed different complications such as the shrinkage, 
contraction and distortion of the surgical meshes, which could lead to chronic pain and 
recurrence (Klinge U. et al., 1998a; Cozad M. et al., 2010). The optimal mesh should 
minimize the complications connected with the wound healing process. This process 
consists of five overlapping stages: haemostasis, inflammation, proliferation, 
contraction, and remodelling (Figure 4; Franz M.G., 2006; Binnebosel M. et al., 2011). 
Implanting a material into a living body can be considered an injury, and likewise 
evokes a cascade of host reactions, including blood-material interactions with the 
formation of a fibrin matrix, inflammation, cellular infiltration, new tissue formation and 
remodelling. After the initial inflammatory response, blood vessels and mesenchymal 
cells will start to approach and eventually invade the implant. The kind of tissue that is 
finally formed depends on the microenvironment to which the migrated cells will be 
exposed (Cobb W.S. et al., 2009; Voskerician G. et al., 2010). 
Important risk factors, besides choosing the proper type of prosthetics and 
operation technique in the abdominal wall hernia development, is the lifestyle patients 
have. The most detrimental negative influence is smoking tobacco. Smokers have a 
four-time higher recurrence rate of ventral hernias in comparison with non-smokers. 
Knuutinen et al. showed that a synthesis of collagen type I and type III are negatively 
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affected by smoking (Knuutinen A. et al, 2002). That can result in a reduction of the 
collagen I/III ration, which causes a decrease of abdominal wall tissue stability (Birk 
D.E. and Mayne R., 1997). The negative ratio of those collagens was also described 
by Klosterhalfen and Klinge, who revealed that tissues surrounding the explanted 
surgical meshes because of hernia recurrence showed a lowered collagens ratio of 
70% (Klosterhalfen B. and Klinge U., 2013). In addition, smokers have matrix 
metalloproteinase enzymes, which degrade the collagens expressed in higher levels, 
possibly causing a decrease in the final tensile strength of the new healed wound tissue 











Figure 4. Phases of wound repair. 
Notes: Adapted from Ather S. and Harding K.G., 2009. 
Other risk factors concerning either the genetic constitution of the collagen 
synthesis and remodelling or other inherited disorders of the connective tissue playing 
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a significant role in hernia development are the Marfan and Ehlers-Danlos syndromes, 
homocystinuria, elastosis and others (Antoniou G. A. et al., 2011). The classic risk 
factors causing impaired wound healing are malnutrition, obesity, diabetes mellitus and 
the use of corticosteroids and immunosuppression (Heniford B.T. et al., 2003; Brem H. 
and Tomic-Canic M., 2007).  
1.3 Basic prosthetics used for incisional hernia repair 
An ideal mesh for use in ventral hernia regeneration should meet a number of 
criteria. The mesh has to be chemically inert, biocompatible, non-carcinogenic, 
capable of being sterilized, should not cause inflammation or an allergic response and 
be unlikely to produce a significant host immune response (Read R.C., 2004; 
Shankaran V. et al., 2011). From the biomechanical point of view the mesh should 
withstand at least tensile strength equivalent to that of the abdominal wall, which is 16 
Ncm-1 (Klinge U. et al., 1996). In addition, the mesh should be largely producible in an 
affordable manner (Shankaran V. et al., 2011).  
1.3.1 History of prosthetics in abdominal wall hernia repair 
The very first surgical mesh for hernia repair was developed in 1900 in Germany 
by Witzel and Goepel. They made the mesh as a silver filigree by hand (Figure 5; 
Witzel O., 1900; Goepel R., 1900). Silver was assumed to be bactericidal, but the mesh 
was rigid, corrodible when in contact with tissue fluids, and with a higher risk of fistula 
forming, caused problems. Another mesh was made from the inert metal tantalum in 
the 1940s (Jefferson N.C. and Dailey U.G., 1948; Koontz A.R., 1948). Unfortunately, 
tantalum caused small bowel fistula, ulceration and the metal fragments eroded 
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through the peritoneum and skin after the repeated flexion of the tissues 











Figure 5. Different previous prosthetics made from either silver filigree or tantalum. (A, B, C) Silver 
filigree meshes. (D) Tantalum gauze. 
Notes: Adapted from Mayer W.,1902; McGavin L., 1907; Burke G.L., 1940. 
At the same time, Nylon, the first plastic prosthesis, became widely available. The 
first reported use of Nylon as a suture in herniology was reported by Melick (Melick 
D.W., 1942). A monofilamtous nylon suture successfully used by Moloney et al. 
(Moloney G.E. et al., 1948) replaced silk, which was associated with a foreign body 
reaction and sepsis (Handley W.S., 1918). Aquaviva and Bounet began using it in 
France in the form of a mesh during World War II (Aquaviva D. and Bounet P., 1944). 
Nylon was later replaced by other plastics because it lost 80% of the tensile strength 
during its hydrolysis and denaturation in time and had to be removed in the presence 
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of infection (Koontz A.R. and Kimberly R.C, 1959; Adler R.H. and Firme C.N., 1957). 
The use of another synthetic polymer in the form of a knitted mesh for incisional hernia 
repair was described in animal studies by Usher et al. in 1958 (Usher F.C. et al., 1958). 
This surgical mesh made from polypropylene with the present commercial names 
Marlex® or Prolene® are the most widely-used prosthetic material for repairing ventral 
hernias to date (Amid P.K. et al., 1995, Cobb W.S. et al., 2009).  
A second synthetic polymeric material with the commercial name Dacron® or 
Mersilene® commonly used to date is based on polyesters (Wolstenholme J.T., 1956; 
Shankaran V. et al., 2011). Rives and Stoppa successfully used polyesters for “pre-
peritoneal” placement in hernia repairs (Rives J., 1967; Stoppa R.E., 1989). A third 
very often used prosthetic material was developed from polytetrafluoroethylene (PTFE) 
to its expanded porous form in the 1970s (Gore R.W. et al., 1976). The last main group 
of surgical meshes includes biologic meshes and different composites that have 
become increasingly popular in recent years. 
1.3.2 The most widely used prosthetics nowadays 
In general, non-resorbable synthetic meshes could be divided into 4 main groups. 
Polypropylenes (Prolene®, Marlex®, Vypro®, ProLite™, etc.), polyesters (Dacron®, 
Mersilene®, etc.), expanded polytetrafluoroethylenes (ePTFE, Goretex®, etc.) and 
composites (Sepramesh™, Proceed®, Parietex™, etc.) The group of absorbable 
synthetics includes glycolic acid (Vicryl®), polyglycolic acid (Dexon™), and 
carboxycellulose (Seprafilm®). It is very difficult to choose a proper one from the large 
number of classifications of surgical meshes. Many different ways of classifying have 
been presented (Klinge U. and Klosterhalfen B., 2012; Coda A. et al., 2012). 
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In addition to synthetic meshes, there are a few commercially-available biological 
meshes with appropriate biocompatible features, e.g. derived bovine pericardium 
(Tutomesh®), acellular porcine dermis (Permacol™) and an acellular analogue of the 
human dermis (AlloDerm®). However, the use of xenografts is nowadays on the 
decline, and the production of this type of mesh is limited by the extremely high cost.  
1.3.2.1 Polypropylenes 
Polypropylene-based meshes are the most widely-used prosthetics for hernia 
repair, with more than 1 million implantations each year in the United States (Cobb 
W.S., et al., 2005, Cobb W.S., et al., 2009). Polypropylene is a hydrophobic polymer 
extremely resistant to biological degradation by tissue enzymes (Read R.C., 2004) and 
in general represent non-degradable polymers. However, its degradation occurs 
through free radicals and the oxygen attack of the methyl groups that produce small 
chain fractures and chemical by-products such as aldehydes and carboxylic (Costello 
C.R. et al., 2010; Cozad M.J. et al., 2010). Polypropylene is most often used in the 
form of a knitted mesh because it allows the increase of porosity and flexibility, as well 
as having identical mechanical properties in all directions (Cobb W.S., et al., 2009). 
Although the most commonly used polypropylene prosthetics are monofilament 
heavyweight meshes Marlex® and Prolene® (Amid P.K. et al., 1995, Cobb W.S. et al., 
2009), the lightweight polypropylene meshes e.g. Vypro® or ProLite™ appear to have 
some significant advantages such as large pore size, a reduced amount of alloplastic 
material and lower foreign body reaction, with the preservation of appropriate tensile 
strength (Klosterhalfen B. et al., 2005). In addition, Klinge et al. compared the elasticity 
of the human abdominal wall obtained from cadavers with both types of polypropylene 
meshes and discovered that a lightweight mesh imitates human tissue more closely 
(Klinge U. et al., 1998b). Moreover, patients who underwent hernia repair using the 
28 
 
Vypro® mesh complained of chronic pain and a stiff abdomen less often than patients 
with heavyweight hernia repair (Schmidbauer S. et al., 2005). This results are in 
concordance with the study of Klosterhalfen and Klinge, who showed that large pore 
polypropylene meshes (Vypro®, Ultrapro®) in comparison with small pore 
polypropylene meshes (Marlex®,  Prolene®, Atrium®) caused relatively less 











Figure 6. Different kinds of currently used surgical meshes. (A) Prolene® polypropylene mesh. (B) 
Marlex® polypropylene mesh. (C) Mersilene® polyester mesh. (D) Proceed® composite mesh. (E) 
Parietex™ composite mesh. (F) Knited Vicryl® absorbable mesh. (G) ePTFE polypropylene 
composite mesh. (H) AlloDerm® polypropylene composite biologic mesh. (I) Permacol™ biologic 
mesh. 
Notes: Adapted from LeBlanc K.A., 2013; Klosterhalfen B. et al., 2005; Klinge U., 2008; Deeken 




Polyethylene terephthalate (PET) is a multifilament, non-resorable, hydrophilic 
polymer produced by polymerisation from ethylene glycol and terephthalic acid. 
Dacron® was the first commercial polyester for inguinal and abdominal hernia repairs 
used by Wolstenholme (Wolstenholme J.T., 1956). Its newer elastic macroporous form 
was called Mersilene® (Knott J.I., 1961). Current study results regarding the 
effectiveness and safety of using polyesters for hernia repairs are very confusing. On 
the one hand Wantz successfully used Mersilene® and showed its ability to adapt to 
abdominal wall curves and guarantee encapsulation due to a fibroblastic response 
(Wantz G.E., 1991). In addition, short-term swine studies demonstrated significantly 
less contraction, higher incorporation and lower visceral adhesion rates with a 
polyester mesh in comparison with a polypropylene mesh (Gonzalez R. et al., 2005; 
Burger J.W. et al., 2006). On the other hand, in the study of Leber et al., Mersilene® 
hernia repairs revealed higher infection, recurrent rates and levels of fistula formation 
in comparison with the polypropylene mesh (Leber G.E. et al., 1998).   
1.3.2.3 ePTFEs 
PTFEs provides chemical inertness due to their covalent bond between carbons 
and fluorides in a long carbon chain backbone. The expanded form was fabricated 
through a combination of the PTFE nodes interconnected by the PTFE fibrils (Gore 
R.W. et al., 1976). Klinge et al. described a few advantages of using ePTFE in ventral 
hernia repair. ePTFE in that study demonstrated both a lesser adhesion formation and 
low inflammatory reaction of the human body in comparison with heavyweight 
polypropylene (Klinge U. et al., 1999). Unfortunately ePTFE also has a higher 
recurrence level and undergoes shrinkage at a range from 0 to 24% (Klinge U. et al., 
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1999, Schoenmaeckers E.J. et al. 2009).  Another comparison of the same kind of 
meshes in a rabbit animal study showed that polypropylene had superior tissue 
integration but it also incited a more intense inflammatory foreign body reaction (Bellon 
J.M. et al. 1996). In conclusion ePTFE is not entirely appropriate for preperitoneal 
placement due to its lower tensile strength and small pore size, which does not allow 
the ingrowth of the tissue. The intraperitoneal implantation of ePTFE seem to be more 
suitable because that allows exposing it to the viscera (Bellon J.M. et al. 1996, 
Shankaran V. et al., 2011). 
1.3.2.4 Composite meshes 
There are several composite meshes on the market based on e.g. polypropylenes 
and polyesters. These composites combine the tensile strength of the surgical mesh 
base with absorbable or permanent coatings. The coatings are tasked with reducing 
adhesion, inflammatory response, decreasing fibrosis and the contraction of the mesh 
(Scheidback H. et al., 2004).  Several studies proved some of these effects by using 
some of the coated meshes. 
Table 2. Different types of composite meshes and the description of their compound. 
Notes: Adapted from Shankaran V. et al., 2011; Jacob B.P. and Ramshaw B., 2013. 
Name/Brand Description 
C-QUR™ Lightweight polypropylene coated with Omega-3 fatty acid 
Parietex™ PET coated with collagen-polyethylene-glycerol 
Proceed® 
Lightweight polypropylene/polydioxanon coated with oxide 
regenerated cellulose 
PolyPro Hydrocoat™ Polypropylene coated with polyether urethane urea 
Sepramesh™ Polypropylene coated with carboxy-methylcellulose 
Ti-Mesh Lightweight polypropylene covalently covered with titanium 
Ultrapro® Lightweight polypropylene coated with polyglecapron 
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In the short-term outcomes, most of the composite meshes successfully reduced 
adhesions and decreased the inflammatory response (Jacob B.P. et al., 2007; Judge 
T.W. et al., 2007), however the coatings were unstable over time and disintegrated 
(Sehreinemacher M.H. et al., 2009). The different types and the description of coatings 
of the composite meshes are summarised in Table 2.  
1.3.2.5 Absorbable meshes 
Absorbable prosthetics are generally applied for temporary abdominal closure, or 
are used in conjunction with permanent synthetics (Shankaran V. et al., 2011). These 
meshes demonstrated some advantages in the long-term outcomes. They reduce the 
risk of adhesion formation and foreign body reaction (Jacob B.P. and Ramshaw B., 
2013). Absorbable meshes are mostly composed of polylactic acid and polyglycolic 
acid in the form of their copolymers (Dexon™, TIGR®) in potential combination with 
e.g. polyglycin or trimethylene carbonate (Vicril®, GORE® Bio-A®), or carboxycellulose 
(Seprafilm®) and polyglycolic acid (Safil®) alone. The important feature of the 
absorbable meshes is also the different degradation rate. When the mesh degrades 
too fast it could lose the tensile strength and thus cause a recurrence. On the other 
hand when the mesh degrades too slowly it may induce a long-term foreign body 
reaction (Jacob B.P. and Ramshaw B., 2013; Bendavid R. et al., 2001). 
1.3.2.6 Biologic meshes 
Bioprosthetics belong among the newest materials used for wall hernia repair. 
These meshes are derived from the collagen-rich tissues of a human, porcine or bovine 
donor from different sites such as the dermis (AlloDerm®, Permacol™, Strattice™), 
small intestine submucosa (Surgisis®) and the pericardium (Tutomesh®, Peri-Guard®). 
The tissues are decellularized with different methods e.g. with sodium deoxycholate or 
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sodium hydroxide. With this treatment we obtain a collagen, elastin and laminin 
scaffold that can be repopulated and neo-vascularized. Precisely, the neo-
vascularisation and incorporation into host tissue may allow a biological scaffold to use 
it in contaminated or infected surgical wounds (Milburn M.L. et al., 2008; Hiles M. et 
al., 2009). The biologic scaffolds may also be cross-linked to increase their 
cohesiveness and preserve the structure for a longer period (Gaertner W.B. et al., 
2007). However, several studies demonstrated that the biologic matrix modified with 
specific manufacturing and/or crosslinking may lead to a negative response of the host 
to such material (Jarman-Smith M.L. et al., 2004; Sandor M. et al., 2008). A negative 
limitation of this type of meshes is their potential disease transmission (Peppas G. et 
al., 2010). There were reported cases in the literature about prion-related disease 
transmission from allografts or the risks of the host immune response development 
due to residues of deoxyribonucleic acid (DNA) fragments in the xenografts, despite 
the sterilisation and the decelularisation process (Peppas G. et al., 2010; Gilbert T.W. 
et al., 2009).  
Despite the inalienable advantages of biologic scaffolds, most of them are 
xenografts subject to the strict control and approval of the Food and Drug 
Administration (FDA) and European Medicines Agency (EMA). Moreover, these grafts 
generally cost ten times more than the synthetic meshes. Heterografts cost 
approximately 20% less than allografts (Peppas G. et al., 2010; Rosen M.J., 2010). 
More specifically some sources compared the prices of a e.g. human acellular dermal 
matrix ($26.00/cm2) and bovine or porcine-based scaffolds ($8.60 - $22.00/cm2) with 
polypropylene mesh ($1.00/cm2) or absorbable Vicryl® mesh ($0.20/cm2; Bachman S. 
and Ramshaw B., 2008; Blatnik J. et al., 2008; Peppas G. et al., 2010). 
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1.4 Nanofibers in tissue engineering 
As previously mentioned, the optimal prosthetic for abdominal wall repair should 
meet a number of criteria. The mesh has to be chemically inert, biocompatible with 
sufficient biomechanical properties, and should not cause inflammation or an allergic 
response (Read R.C., 2004; Shankaran V. et al., 2011). One way to improve the 
properties of the meshes used until now is to combine them with other tissue-
engineered materials, or to replace the meshes completely through these materials.  
Highly-porous scaffolds with interconnected pores are favoured in tissue 
engineering applications (Sato T. et al., 2004). Much attention has been paid to the 
application of biodegradable microfibers and nanofibers. Nanofiber scaffolds produced 
e.g. by electrospinning contain a large number of interconnected pores and fibers in 
the diameter of the ECM (Khil M.S. et al., 2005). In living systems, the ECM plays a 
pivotal role in controlling cell behaviour, such as adhesion, proliferation, migration, and 
differentiation (Kim S.H. et al., 2011). An optimal scaffold, particularly a surgical mesh 
designed in tissue engineering, should mimic natural ECM. Such a mesh would create 
the finest microenvironment for cell adhesion and proliferation. Clearly, nanofibrous 
scaffolds meet these requirements not only due to their topography, but also due to 
their high surface-to-volume ratio and the possibility of modifying their surface and also 
interior to improve biocompatibility (Ma Z. et al., 2005a; Agarwal S. et al., 2008). In 
recent years, for example, the electrospinning method has been applied for this 
purpose, as it is a simple and cost-effective way to fabricate fibers both from synthetic 
polymers and other substances (Lukas D. et al., 2009). The topographical features of 
the fibers can easily be adjusted to fit specific applications by controlling various 
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parameters (Lukas D. et al., 2009; Bhardwaj N. and Kundu S.C., 2010; Grafahrend D. 
et al., 2011). 
1.4.1 Fabrication of nanofibers through the electrospinning method 
Nanofibers for tissue engineering fabricated e.g. by electrospinning, are 
produced from materials that are biocompatible and mostly biodegradable or non-
biodegradable. Nowadays, electrospinning has gained attention as one of the most 
efficient submicrometer fiber-forming fabrication processes (Cipitria A et al., 2011). To 
date more than 200 different polymeric materials have been successfully electrospun 
(Bhardwaj N. and Kundu S.C., 2010). These polymers may have a synthetic origin 
such as poly--caprolactone (PCL; Kim T.G. and Park T.G., 2006), polyvinyl alcohol 
(PVA; Chuangchote S. and Supaphol P., 2006), polylactic acid (PLA; Yang F. et al., 
2005), poly(lactic-co-glycolic) acid (PLGA; Kim T.G. and Park T.G., 2006), 
polyurethanes (PU; Khil M.S. et al., 2003) or natural origin such as collagen (Matthews 
J.A. et al., 2002), fibrin (Carlisle C.R. et al., 2009), silk (Ohgo K. et al. 2003)  chitosan 
(Jayakumar R. et al., 2010), cellulose (Ma Z.W. et al., 2005b) and hyaluronic acid (Um 
I.C. et al., 2004).  
1.4.1.1 Principles of electrospinning 
The principle of the electrospinning method is based on the influence of a high 
voltage electric field to polymer solutions. The electrostatic forces are induced due to 
attractive forces between the charged electrode with the polymer and the conversely 
charged collecting electrode. A role is also played by the repulsion among identically 
charged molecules inside the polymer solution. Above a certain critical value of the 
applied electric field strength the surface of the polymeric liquid starts to form an 
instability. This instability results in the development of “Taylor cones” due to the 
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balance formed between electrostatic forces arising from a high voltage electric field 
and the surface tension of liquid. The electrospinning jets are formed on the wave 
crests of these “Taylor cones”. As the jets move towards the collecting electrode the 
solvent evaporates and the ultrafine fibers are produced (Lukas D. et al., 2008; Lukas 
D. et al., 2009). 
The basic electrospinning device set-up requires a high-voltage source, a 
capillary tube or a syringe, a mattering pump for the continuous supply of the polymer 










Figure 7. Schematic diagram of an electrospinning device set-up. 
Notes: Adapted from Lukas D. et al., 2008. 
1.4.1.2 Basic electrospinning methods 
In general, electrospinning can be basically classified into either needle or 
needleless electrospinning according to the spinneret and spinning method. The group 
of needle electrospinning includes basic capillary electrospinning and sophisticated 
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core-shell electrospinning, which is divided into emulsion and coaxial electrospinning. 
Needleless electrospinning is using the self-organization of fiber jets on a free polymer 
liquid surface. 
Capillary electrospinning using a needle-like spinneret is based on spinning from 
a droplet. Polymer solutions are supplied on the tip of a thin capillary where a droplet 
forms. The capillary is connected to a high voltage supply and thus the electrospinning 
process may occur between the droplet on the tip and a collecting electrode (Figure 
7). The advantages of this system is its simplicity and the potential to electrospin many 
different polymers. On the other hand this system has low productivity and the 
maintenance of the apparatus is difficult (Teo W. and Ramakrishna S.A., 2006). 
Productivity can be increased with the parallel arrangement of the capillaries. However, 
the usage of more capillaries leads to the deformation of the electric field and the 
arising of adverse effects in the electrospinning process (Teo W. and Ramakrishna 
S.A., 2006). 
Another basic type of electrospinning is based on the self-organization of fiber 
jets on a free liquid surface without using a capillary electrode (Lukas D. et al., 2008b). 
The simplest set-up consists of a bulky metallic rod with a diameter of approximately 1 
cm serving as an electrode. On the top of the electrode there is deposited a very 
viscous hemispherical polymer droplet. The high voltage electric field results in the 
forming of many “Taylor cones “ and intensive nanofiber production (Figure 8; Lukas 
D. et al., 2009). 
A less frequently used system consists of a container with a polymer solution and 
paramagnetic microparticles. The tips of the paramagnetic microparticles are raised 
from the solution in the electric field and allows the formation of polymer fiber jets (Yarin 
A.L. and Zussman E., 2004). Another interesting system is based on a perforated 
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cylinder as an electrode. The polymer solution flows through the holes to the surface 
of the cylinder. Within the electric field many fiber jets are formed and nanofibers are 








Figure 8. The self-organisation of fiber jets on a free liquid surface. At zero field strength, the 
viscous droplet has a hemispherical shape (left-hand side of the figure). In the critical value of the 
electric field intensity, the liquid polymer jets are self-organised (right-hand side of the figure).  
Notes: Adapted from Lukas D. et al., 2009. 
The most important system from needleless electrospinning is the Nanospider™ 
(Jirsak O. et al., 2006). This system is based on a rotating cylinder electrode rinsed 
directly in a polymer solution. Due to the rotation the polymer creates a thin layer on 
the electrode surface, resulting in the formation of many “Taylor cones” and the 
production of a big amount of nanofiber material (Figure 9). Therefore the 
Nanospider™ system is often used for high production and the industrial usage of the 
nanofibers. The competitive device is based on electrospinning from a rotating disk 
electrode (Figure 9, Niu H. et al., 2009). In these systems the extent of the nanofiber 
formation depends on the polymer concentration, the intensity of the electric field and 











Figure 9. Schematic illustration of needleless electrospinning with a high productivity of nanofibers 
and photos of the electrospinning processes. (A) System based on the electrospinning from a rotating 
disk electrode. (B) The Nanospider™ system based on electrospinning from a rotating cylinder 
electrode.  
Notes: Adapted from Niu H. et al., 2009. 
One of the younger electrospinning methods that have gained attention among 
others due to the high potential of being used as drug delivery systems is core-shell 
electrospinning. Core-shell electrospinning could be basically divided into emulsion 
electrospinning from a blend and coaxial electrospinning. Emulsion electrospinning is 
based on nanofiber production depending on the immiscibility of the two polymer 
solutions, called a blend (Figure 10). One of the polymers is present in a continuous 
phase and another as droplets covering this continuous phase (Agarwal S. and Greiner 
A., 2011). Emulsion electrospinning can use needle or needleless electrospinning 
technique. The crucial point of emulsion electrospinning is the emulsification process 
of the core materials, including different soluble drugs in the fiber forming shell 
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materials and core-shell nanofibers from this emulsion in the electrospinning process 








Figure 10. Schematic illustration of emulsion core-shell electrospinning. Important emulsification of 
a core material with a soluble drug in a fiber forming shell material allows the formation of core-shell 
nanofibers.  
Notes: Adapted from Agarwal S. and Greiner A., 2011. 
The coaxial electrospinning first introduced by Sun et al. is an especial type of 
capillary electrospining (Figure 11; Sun Z.C. et al., 2003). The spinning electrode 
consists of two capillaries that are placed together coaxially. This technique allows the 
production of nanofibers from polymers that either could not be electropun together 
(Teo W.E. and Ramakrishna S.A., 2006) or one of the polymers used as a core material 
being along non-spinnable (Lukas D. et al., 2009). Using a water soluble polymer as 
the core material during coaxial electrospinning allows the obtainment of hollow 
nanofibers after subsequent washing in a water solution (Sun Z.C. et al., 2003). Coaxial 
electrospinning finds a wide application in the field of drug delivery systems (Sun Z.C. 
et al., 2003; Zhang Y.Z. et al., 2004). It enables the incorporation of various bioactive 
substances such as antibiotics, drugs, DNA, proteins and even living cells and affords 
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protection from the environment by the shell material (Reznik S. et al., 2006; 









Figure 11. Coaxial electrospinning of nanofibers. Two immiscible polymer solutions (red and blue) 
are supplied through two concentric needles connected with a high voltage power supply. A 
compound “Taylor cone” is formed from which a coaxial fiber jet is emitted. On the lower right-hand 
side of the figure is a view of the sample after cutting  
Notes: Adapted from Loscertales I.G. et al., 2004.  
1.4.1.3 Collecting electrodes (collectors) 
Grounded or charged collecting electrodes play important role in the productivity 
of nanofibers and can result in the final mesh properties. Using the simple non-
structured collectors results in the formation of randomly oriented nanofiber meshes. 
As a collector most often a metal plate made from aluminium or copper is used (Lukas 
D et al., 2009; Teo W.E. and Ramakrishna S.A., 2006). Modified collectors enable the 
fabrication of a structured nanofibers layer. The depositing of the nanofibers onto the 
collector is affected by its shape and the arrangement of the conductive and non-
conductive parts (Lukas D. et al., 2009; Teo W.E. and Ramakrishna S.A., 2006). One 
of those kinds of collectors has projections that affect the depositing of the nanofibers. 
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The nanofibers are deposited onto the collector not only as a planar mesh but form a 
specific 3D structure (Lukas D. et al., 2009). Another kind of collector is represented 
by a rotating cylinder or disk. With an appropriate speed setting the electrospun 
polymer forms an oriented layer of nanofibers (Matthews J.A. et al., 2002). The 
depositing of the oriented nanofiber is also the result of static collectors composed from 
parallel conductive wires, circles or slices (Teo W.E. and Ramakrishna S.A., 2006).  
1.4.1.4 Basic controlling factors and parameters for the modification of 
nanofiber features  
Electrospinning is affected by a large amount of parameters that can modify the 
features of a nanofiber scaffold.  
The basic parameter is a voltage value applied for the electrospinning process. 
The increase in applied voltage results in the different structural morphology of 
nanofibers. Deitzel et al. observed that higher voltages cause the formation of bead 
fibers with a thick diameter (Deitzel J.M. et al., 2001). 
The distance of the electrode from the collector affects the intensity of the electric 
field and thereby the morphology of the nanofibers. With increasing distance the 
intensity per square unit is decreasing, resulting in the weakening of the electrostatic 
forces and forming a thinner fiber. When the distance reaches a critical value the 
“electrospraying” phenomenon occurs and the polymer droplets instead of fibers are 
formed (Doshji J. and Reneker D.H., 1995).  
The speed of the polymer solution supply affects the width and morphology of 
nanofibers. When using a high speed of supply the solvent is not completely 
evaporated, resulting in an accumulation of either the non-fiber layers or the fibers with 
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a changed morphology. The usage of the lower speed supply forms nanofiber with a 
smaller diameter (Yuan X.Y. et al., 2004) 
The molecular weight and concentration of the polymer affects the rheological 
and electrical features of the polymer solution. Both the higher molecular weight and 
the higher concentration of polymer increases the thickness of the nanofibers (Haghi 
A.K. and Akbari M., 2007; Cui W.G. et al., 2010). 
The volatility of the solvent is a very important factor that could change the 
nanofibers structure. In the case of insufficient solvent volatility the liquid polymer 
solution is deposited onto the collector and forms non-spun layers (Bhardwaj N. and 
Kundu S.C., 2010). When the volatility is too high the solvent quickly evaporates and 
the deposited nanofibers have a porous surface (Sill T.J. and von Recum H.A., 2008). 
Electrospinning is also affected by environmental factors such as the temperature 
of polymer solution, ambient temperature, and humidity (Lukas D. et al., 2009) 
1.4.2 PCL nanofibers in tissue engineering 
In general, nanofibers prepared by electrospinning is one of the most promising 
scaffolds used in tissue engineering. Tissue engineering is focused on the reparation 
of damaged tissues and organs. The main field of PCL nanofibers scaffold use is the 
regeneration of cartilages, tendons, bones, nerves and skin. As mentioned before PCL 
nanofibers create the finest microenvironment for cell adhesion, proliferation and 
differentiation by mimicking natural ECM (Khil M.S. et al., 2005). 
PCL is a semi-crystalline, aliphatic polyester that is non-toxic, biodegradable, 
biocompatible and is used in pharmaceutical products and wound dressings (Ng K.W. 
et al., 2001). In addition this polymer is relatively inexpensive, chemically stable, rather 
hydrophobic and highly elastic with good mechanical properties and a slow 
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degradation rate. It degrades within 6-24 months as a result of the hydrolysis of its 
ester linkages. The degradation process is non-enzymatic hydrolytic cleavage followed 
by intracellular degradation in the phagosomes of the macrophages and giant cells 
(Woodward SC et al., 1985). Moreover, PCL has frequently been chosen for scaffold 
fabrication in tissue engineering, because it is an FDA-approved material and has been 
shown to support the attachment and growth of chondrocytes (Jakubova R. et al., 
2011), osteoblasts (Hutmacher D.W. et al., 2001; Kweon H. et al., 2002), smooth 
muscle cells (Thapa A. et al., 2003), fibroblasts (Hutmacher D.W. et al., 2001; Chen 
M. et al., 2007), myoblasts (Williamson M.R. and Adams E.F., 2006), and 
mesenchymal stem cells (MSC; Rampichova M. et al., 2013).  
Tissue engineering focusing on cartilage regeneration is a promising tool for 
arthroses and mechanical cartilage impairs healing. The three-dimensional PCL 
nanofiber scaffold seeded with foetal bovine chondrocytes was prepared and tested 
by Li et al. Chondrocytes cultivated on this scaffold kept their phenotype and 
expression of chondrogene markers such as collagen type II and glycosaminoglycans 
(Li W.J., et al. 2003). A later work of this group demonstrated the differentiation of 
human MSCs cultivated on that scaffold from chondrocytes by using the addition of 
beta 1 transforming growth factor (TGF-β1; Li W.J. et al., 2005). 
In bone tissue engineering the nanofiber scaffolds should meet the criteria for 
mechanical stability, morphology, porosity and prolonged biodegradability (Vasita R. 
and Katti D.S., 2006). Promising nanofiber scaffolds are fabricated by the 
electrospinning of a PCL solution, including hydroxyapatite particles 
(Wutticharoenmongkol P. et al., 2006). 
Ligaments and tendons are created with dense ECM and tenocytes. The 
damages of tendons leads to the altered function of joints, which could cause 
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irreversible changes in the musculoskeletal system. The usage of a tissue engineered 
scaffolds enables the improvement of present surgical methods of damaged ligaments 
and tendon repair. For these purpose it seems most appropriate to use the nanofiber 
scaffolds formed withoriented PCL fibers (Kim G.H, 2008).  
The regenerative potential of the nervous system is limited and its damage is 
difficult to treat. Oriented PCL nanofiber layers enable the growth of axonal dendrites 
and the migration of glial and Schwan cells (Schnell E. et al., 2007). Panseri et al. even 
proved that an electrospun micro-nanotube scaffold made from PCL and PLGA lead 
to the regeneration of a 10 mm long gap in rat ischiadic nerves (Panseri S. et al. 2008). 
PCL appears to be a suitable material for scaffold preparation for reparative 
surgery. It has been used in several preclinical trials for wound healing (Venugopal 
J.R. et al., 2006; Ng K.W. et al., 2007; Liu X. et al., 2010; Kobsa S. et al., 2013), and 
could be used in combination with a surgical mesh in ventral hernia regeneration.  
1.5 Drug delivery systems based on PCL nanofibers 
Nanofibers in combination with drug delivery systems positively affect the 
physiological state of various cells and enable the creation of an appropriate 
microenvironment proximate to the tissue defect (Agarwal S. et al., 2008).  
1.5.1 Adhesion of bioactive substances onto PCL nanofibers 
Nanofibers in general have an interconnected porous structure and a high 
surface-area-to-volume ratio, permitting the adsorption and high immobilization of 
drugs (Canbolat M.F. et al., 2004), antibiotics (Dave R. et al., 2009) and growth factors 
(Matlock-Colangelo L. et al., 2014) as well as blood derivatives such as platelet-rich 
plasma (PRP; Hromadka M.C. et al., 2008). An interesting example of a scaffold with 
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adhered bioactive substances are nanofibers coaxially electrospun from a PCL core 
and a cationized gelatine shell (Lu Y et al., 2009). Onto the shell it is possible to adhere 
a negatively charged ligand such as heparin, hyaluronic acid, bovine serum albumin 
(BSA) or other proteins and nucleic acid. The adhesion of heparin and BSA enables 
the subsequent specific interaction with a vascular endothelial growth factor (VEGF) 
and basic fibroblast growth factor (bFGF; Lu Y et al., 2009). Another simple drug 
delivery system based on the adhesion of bioactive substances onto PCL nanofibers 
was developed in our group. Human platelets were adhered onto PCL nanofibers and 
scaffolds were tested in vitro by porcine chondrocyte cultivation (Figure 12; Jakubova 
R. et al., 2011). Growth factors were released from the platelet adhered to the 










Figure 12. Cryo-Scanning electron microscopy (CryoSEM) visualization of a platelet adhered to PCL 
nanofibers. 
Notes: Adapted from Jakubova et al., 2011. 
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1.5.2 Core-shell PCL nanofibers as a drug delivery system 
Another option for fabricating a drug delivery system based on nanofibers is to 
use either electrospinning from a mixture of bioactive substance and electrospun 
polymer (composite blend) or coaxial electrospinning. Electrospinning from the blend 
is a simple one-step method enabling the incorporation of many bioactive substances 
(16). The limiting factor is the compatibility of a transferred bioactive substance with a 
polymer solvent. The most appropriate polymer for this type of drug delivery system 
fabrication is PVA and polyethylene glycol (PEG). These polymers can mimic the 
biomolecules and enable the development of secondary binding to the transferred 
substances and thus stabilise them (Wang Z.G. et al, 2009). The blend electrospinning 
technique was used for the incorporation of different antibiotics (Bolgen N. et al., 2007), 
drugs (Xie J. and Wang C.H. et al., 2006), proteins (Zeng J. et al., 2005) and DNA 
(Liang D. et al., 2005). The ability to preserve the bioactivity of proteins in the 
nanofibers were proven by the incorporation of e.g. alkaline phosphatase, β-
galactosidase (Dror Y. et al., 2008) and horseradish peroxidase (HRP; Patel A.C. et 
al., 2006). 
Coaxial electrospinning is a promising strategy for the delivery of required 
bioactive substances. One big advantage of this technique for producing core-shell 
nanofibers consist in the preservation of biomolecules during the electrospinning 
process. A second important advantage enables the combination of water non-soluble 
polymers with bioactive molecules not compatible with a non-polar solvent. The 
hydrophilic core polymers such as PVA, PEG or polyethylene oxide (PEO) enable the 
loading of biomolecules, whereas the hydrophobic shell e.g. PCL assigns fiber 
formation (Saraf A. et al., 2009). The rate of bioactive molecules released from the 
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nanofibers depends exactly on the content of the degradable core components (Jiang 










Figure 13. Coaxially electrospun PVA-core/PCL-shell nanofibers with encapsulated liposomes. (A, 
B) Field emission scanning electron microscopy (FESEM) of embedded liposomes within PVA/PCL 
nanofibers. (B) Detail of an incorporated intact liposome. (Insert) Pure PVA/PCL nanofibers without 
liposomes as a control. (C, D) Confocal microscopy of PVA/PCL nanofibers either (C) with 
encapsulated liposomes containing fluorescein or (D) without liposomes but with the addition of 
fluorescein in the core showing distribution throughout all nanofibers.  
Notes: (A, B) scale bars 300 nm, (C) scale bar 20 µm, (D) scale bar 50 µm,  (Insert) 2 µm. Adapted 
from Mickova A. et al. 2012.  
Coaxial nanofibers have been used for the incorporation of various bioactive 
substances such as antibiotics, drugs, DNA, and proteins (Sill T.J. and von Recum 
H.A., 2008; Ji W. et al., 2010). In addition, Sahoo et al. prepared core-shell nanofibers 
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through a blend and coaxial electrospinning for the delivery of bFGF. The presence of 
the growth factor in coaxial nanofibers led to increasing MSC proliferation (Sahoo S. 
et. al., 2010). In another work bFGF encapsulation with BSA for fibroblast proliferation 
stimulation of PCL/PEO coaxial nanofibers were used (Rubert M. et al., 2014). 
Moreover, coaxial nanofibers based on a PCL shell and PVA core with encapsulated 
liposomes as a promising controlled drug delivery system was developed and analysed 
in our group (Figure 13; Mickova A. et al., 2012) 
1.5.3 Other examples of drug delivery system based on nanofibers 
The last main group of a drug delivery system using nanofibers is based on the 
covalent immobilisation of bioactive substances onto the scaffold surface. These types 
of systems are more difficult for preparation and their application is more specific. 
Monteiro et al. prepared a chitosan nanofiber mesh with gentamicin-loaded liposomes 
immobilised on their surface. The nanofiber surface was modified with thiol groups that 
enabled the covalent binding of the liposomes. This functionalised nanofiber could be 
used as a promoter of antibacterial activity in human wound dressing (Monteiro N et 
al., 2015). Another system based on nanofibers with covalent immobilised bioactive 
substances was prepared by Manahkov et al. and Oktay et al. (Manahkov A. et al., 
2015; Oktay B. et al., 2015). 
1.6 Platelets as a part of tissue engineering 
Nowadays one of the very important widely used components of tissue 
engineered scaffolds are stimulating factors enabling the inducement, acceleration and 
enhancement of tissue regeneration. Synthetic growth factors (GF), platelet derivatives 
as a natural source of GF and other stimulating substances can be applied directly 
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during in vitro cultivation or through incorporation into the drug delivery systems, such 
as nanofiber scaffolds or liposomes.  
Platelets play a primary role in the hemostasis and initiation of the wound healing 
process (White J.G., 1987). On the one hand, platelets are a natural source of various 
growth factors that stimulate healing (Vavken P. et al., 2011). On the other hand, they 
form a clot as a temporary matrix that fills the injury site and provides support for cell 
migration, tissue regeneration and remodelling (Vavken P. et al, 2011). That function 
of platelets could be enhanced or substituted by nanofiber scaffolds.  
1.6.1 Composition of platelets 
Platelets are formed by the fragmentation of big polyploid bone marrow cells 
with a large lobulated nucleus called a megacaryocyte (White J.G., 1987). Platelets 
fulfil their biologic activity mainly by releasing secretory granules. The bioactive 
substances are entrapped within 3 types of granules (a) alpha granules; (b) delta 
granules (dense granules); (c) lambda granules (lysosomes). Among these types the 
alpha granules are the most abundant, containing most of the platelet bioactive 
substances and essential for normal platelet activity (Blair P and Falumenhaft R., 
2009).  
Alpha granules are released from the platelets after activation. Physiologically the 
activation occurs after the adhesion of platelets at the injury site and is mediated 
through the existing collagen layer (Roberts D.E. et al., 2004). Biochemical changes in 
the platelets lead to the release of secretory granules and to changes in platelet 
morphology (Figure 14; Flaumenhaft R. et al., 2003). The release of the content of 
alpha and lambda granules has a positive feedback effect on other platelet activation 
and aggregation at the injury site. The activation of other platelets runs through 
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different mechanisms such as a thrombin haemostatic cascade, autocrine 








Figure 14. Transmission electron microscopy (TEM) of activated platelets. (A) Platelets from a foetus 
with a mutation in the VPS33B gene producing a membrane-associated protein involved in the 
activation pathway. (B) Platelet with alpha granules indicated with white arrows are presented only 
in an unaffected foetus.  
Notes: Scale bars 500 nm. Adapted from Lo B. et al., 2005. 
1.6.1.1 Alpha granules 
Alpha granules contain various bioactive molecules such as growth factors, 
coagulation proteins, adhesive molecules, cytokines, integrins, angiogenic factors and 
other substances (Blair P and Falumenhaft R., 2009). 
Alpha granules are an important source of protein from the TGF-β family, 
consisting of three isoforms (Lawrence D.A., 1996). TGF-β plays an important role in 
the initiation of proliferation and differentiation of the cells of mesenchymal origin. 
Conversely, these growth factors have an inhibitive effect on the proliferation of 
epithelial, endothelial and hematopoietic cells as well as B and T lymphocytes 
(Lawrence D.A., 1996). TGF-β family members enhance the proliferation of 
chondrocytes, stimulate the production of ECM and play regulatory roles in modulating 
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wound healing responses and scarring (Tuli R. et al., 2003). The bone morphogenic 
protein 2 (BMP-2) is also a member of the TGF-β family and plays a crucial role in 
bone epidermis repair (Blokhuis T.J., 2009). 
The epidermal growth factor (EGF) and TGF-α belongs to the same family. The 
biological effect is to increase the glycolysis and synthesis of proteins. It acts as a 
potent mitogen for keratinocytes, other mesenchymal and epithelial cells and 
enhances the migration of cells to the acute wounds (Barientos S. et al., 2008). 
bFGF, also known as  FGF-2, induces proliferation in most of the mesenchymal 
cells, including progenitor mesenchymal stem cells, which helps to keep them in a non-
differentiated state. FGFs also play a role in the re-epithelization, angiogenesis, 
granulation and remodelling of the new tissue (Friesel R.E. and Maciag T., 1995). 
Insulin growth factor 1 (IGF-1) plays a role as a mitogen in the organism. It 
induces cell proliferation and the differentiation of mesenchymal, nervous and epithelial 
cell types. IGF-1 is involved in re-epithelization, the development of the granulation 
tissue and Hers at al. proved that it is essential for vascular wound healing (Madry H. 
et al., 2001; Hers I., 2007) 
The major mitogen of osteoprogenitor cells, osteoblasts, fibroblasts, smooth 
muscle cells and glial cells is the platelet-derived growth factor (PDGF). PDGF plays 
an important role in wound healing, the stimulation of ECM synthesis and chemotactic 
induced MSC migration into the injury site (Heldin C.H. and Westermark B., 1990).  
Some other proteins such as VEGF or thrombospondin-1 presented in the 
platelets are involved in angiogenesis regulation (Italiano J.E. et al., 2008). Platelets 
also contain the Stromal cell-derived factor 1 (SDF-1) involved in MSC and epithelial 
cell migration (Stellos K et al., 2008).  The inflammation reaction is mediated by 
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chemokines such as Interleukin-8 (IL-8), CLXL-4, RANTES and CLXL-7 (Gleissner 
C.A. et al., 2008). Adhesion is induced by the Von Willebrand factor (vWF), fibrinogen 
and fibronectin (Italiano J.E., et al., 2008). 
1.6.1.2 Delta and Lambda granules 
The second type of secretory granules are delta or dense granules. As mentioned 
before they play an important role in the activation of other platelets at the injury site 
either through the non-metabolic fraction of ADP and ATP and purinergic receptors or 
through serotonin action (King S.M. and Reed G.L., 2002). 
The last type of secretory granules are lambda granules. These granules play the 
role of lysozymes in the platelets and include acidic hydrolases, katepsin D, katepsin 
E and other proteins (King S.M. and Reed G.L., 2002). 
1.6.2 Platelet rich plasma and thrombocyte-rich solutions 
Growth factors abundantly present in platelet preparation such as PRP have been 
shown to be effective in promoting wound healing and regeneration in tissue 
engineering (Nauta A. et al., 2011). Preparations derived from platelets were originally 
designed for increasing their numbers in the transfusion therapy of coagulation 
disorders. PRP is defined as a relatively small volume of the plasma fraction with a 
platelet concentration above a certain value. PRP classically contains more than 0.5 × 
1011 platelets per unit (Ehrenfest D.M et al., 2009).  
At present, PRP is usually prepared through the centrifugation of the collected 
blood. During this procedure the blood is divided into four fractions with an 
anticoagulant, red blood cells found at the bottom, acellular plasma also known as 
platelet-poor plasma (PPP), in the supernatant and the “buffy coat”, including 
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leucocytes, appears in between. The “buffy coat” fraction may be either directly applied 
to the surgical site using thrombin for platelet activation and fibrin polymerisation, or 
may be resuspended in the small amount of plasma and used for in vitro application 
(Ehrenfest D.M et al., 2009). Another processing of the “buffy coat” uses the gradual 
depletion of the leucocytes through multistep centrifugation (Anitua E., 1999) with 
subsequent resuspending in a supplement buffer solution (Baenziger N.L. et al., 1971; 
Jakubova R et al., 2011). In the first case we can obtain the previously mentioned PRP 
products and in the second product, called a thrombocyte-rich solution (TRS). The big 
advantage of a TRS preparation not containing leucocytes is the minimizing of the 
immune response when applied. On the other hand the disadvantages is the low yield 
and reproducibility. Some studies also demonstrated the effectivity of using PPP in 
tissue engineering. PPP can improve wound healing when compared with untreated 
controls, but not as effectively as PRP (Pietrzak W.S. et al., 2007; Creeper F. et al., 
2012).  
The in vitro studies demonstrated the ability of different platelet preparation to 
stimulate the proliferation of osteoblasts (Clausen C. et al., 2006), fibroblasts, 
tenocytes (Anitua E. et al., 2005), chondrocytes and MSC (Drengk A. et al., 2009). The 
proliferative effect of the TRS on chondrocytes and on MSCs has been also confirmed 
in our laboratory (Jakubova R., et al., 2011; Buzgo M. et al., 2013). 
The main problem with using different platelet preparations is the immediate 
release of GFs at the injury site, which could lead to some risk connected with high 
doses of GF application. The results from in vitro and in vivo studies indicated that the 
pro-inflammatory effect of platelet preparation could also have a negative effect and its 
dosage should be determined deliberately (Goutallier D. et al., 2003). Particularly, 
Graziani et al. showed that the best effect of the platelet on osteoblast and fibroblast 
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proliferation in vitro was achieved using a concentration 2.5 times higher than the 
physiological concentration of the platelet in human blood. The 2.5-time higher 
concentration caused reduction in the proliferation of those cells (Gaziany F. et al., 
2006). In contrast Yamaguchi et al. had to use a much higher platelet concentration to 
promote anastomotic wound healing in a rat specimen. The effect of PRP was 
observed in the preparation with a concentration of 2×106 platelets/µl (approx. 8 times 
the physiological concentration). The inhibition of healing was observed in the 
preparation with a concentration of 5×106 platelets/µl (Yamaguchi R. et al., 2012). 
Another problem using different platelet preparations is the short-lived therapeutic 
effect of GFs in case they are washed out from the injury site. The solution for both 
complications is to use a platelet preparation in combination with other biomaterials, 
enabling their elimination. We have already mentioned the potential usage of a 
nanofiber scaffold for drug delivery systems. Other described scaffolds using platelet 
preparations are decellularizated bone matrix (Rodriguez A. et al., 2003), fibrin gels 
(Anitua E. et al., 2007) and hydrogel based on alginate and cationized gelatine 








2 Aims of the study 
The study was focused on development and functionalization of scaffolds for 
incisional hernia repair.  
The study includes the following stages: 
1. Preparation and testing of a novel composite scaffold based on a 
polypropylene surgical mesh functionalized with the PCL nanofibers and adhered 
human platelets in vitro. 
2. Testing the composite scaffold based on a polypropylene surgical mesh 
functionalized with the PCL nanofibers and adhered synthetic growth factors in vivo on 
rabbits as a small animal model. 
3. Testing a scaffold based on the PCL nanofibers functionalized with adhered 
human platelets in vivo on minipigs as a large animal model.  
4. Testing the scaffold base on cryogrinded PCL nanofibers with potential use as 








3 Material and methods 
3.1 In vitro testing of the composite scaffold based on a 
polypropylene surgical mesh functionalized with PCL 
nanofibers and adhered human platelets 
3.1.1 Scaffold preparation 
PCL nanofibers were prepared by an electrospinning method from PCL with 
molecular weight MW 45 000 (Sigma-Aldrich, St. Louis, MO, USA; Lukas D. et al., 
2009). Electrospinning was performed from a 14% solution of PCL dissolved in 
chloroform:ethanol with a ratio of 8:2. A high-voltage source generated voltages of up 
to 50 kV, and the polymer solution was connected to a high-voltage source. 
Electrospun nanofibers were deposited on the grounded collecting electrode. A 
polypropylene surgical mesh (PP; Prolene™, Ethicon Inc., Somerville, NJ, USA) was 
coated with PCL nanofibers. Prolene™ was attached to the grounded collector, and 
PCL nanofibers were deposited on the mesh from each side (Figure 15).     
3.1.2 Thrombocyte-rich solution preparation 
Human platelets in plasma was obtained from the Haematology Service of the 
General Teaching Hospital, Prague, Czech Republic. Platelets (volume 200 mL, 
thrombocyte concentration 106 × 107 platelets/mL) was centrifuged (2250 g, 15 min), 
the supernatant was discarded and the resulting platelets were washed in a washing 
buffer (113 mM NaCl, 4.3 mM K2HPO4, 4.3 mM Na2HPO4, 24.4 mM NaH2PO4 and 5.5 
mM glucose, pH 6.5) as described by Baenziger et al (Baenziger N.L. et al., 1971). 
Contaminating leukocytes and erythrocytes were removed by further centrifugation 
(120 g, 7 min). The platelets were washed until the leukocytes and erythrocytes 
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contained in them were removed. The platelets were pelleted by centrifugation (2000 
g, 15 min), and were then washed once and finally resuspended in 10 mL of a pH 7.5 
resuspendation buffer (109 mM NaCl, 4.3 mM K2HPO4, 16 mM Na2HPO4, 8.3 mM 













Figure 15. Methodology of the scaffold fabrication. PCL nanofibers were prepared by an 
electrospinning method. Electrospun nanofibers were deposited on a PP surgical mesh which was 
attached to the grounded collecting electrode from each side. PP covered with PCL nanofibers was 
cut into round patches of 6 mm in diameter, sterilized and immersed in TRS for 2 hours. The non-
adhered platelets were removed by rinsing twice in phosphate buffered saline (PBS; pH 7.4). The 
composite scaffolds were placed in a new well, seeded with 3T3 fibroblasts and tested in vitro. 
Notes: (1) syringe and metering pump, (2) needle serving as the electrode, (3) stable part of the jet, 
(4) whipping/coiling zone, (5) collector covered with PP, (6) ground and (7) high voltage supply. 
Abbreviations: PP, Prolene™; PCL, poly--caprolactone; TRS, thrombocytes-rich solution; PBS, 
phosphate buffered saline.  
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3.1.3 Composite scaffold preparation 
Before cell seeding, PCL nanofibers and Prolene™ coated with PCL nanofibers 
were cut into round patches 6 mm in diameter and sterilized using ethylene oxide at 
37°C. The scaffolds were used one week after sterilisation, in order to air out possible 
remnants of ethylene oxide. The scaffolds were immersed in TRS (106 × 106 
platelets/mL) for 2 hours to enable adhesion of platelets (Figure 13; Jakubova R. et al., 
2011). After the incubation time, non-adhered platelets were removed by rinsing twice 
in PBS (pH 7.4). Scaffolds without adhered platelets were incubated in PBS (pH 7.4) 
for 2 h. Then the composite scaffold was placed in a new well and was seeded with 
3T3 fibroblasts. Growth factors were released from the platelets adhered to the 
nanofibers over a period of 1 - 14 days (Buzgo M. et al., 2013). 
3.1.4 Scanning electron microscopy and stereological analysis of the 
scaffolds 
Nanofibers were sputter-coated with a layer of gold approximately 60 nm in 
thickness using a Polaron Sputter-coater (SC510, Polaron, Quorum Technologies Ltd, 
East Gristead, UK). The samples were examined in an Aquasem scanning electron 
microscope (Tescan, Brno, Czech Republic) in secondary electron mode at 15 kV.  
The electrospun scaffolds were characterized in terms of fiber diameter and pore 
size using mathematical stereological methods, as described in detail previously 
(Mickova A. et al., 2012). Briefly, the stereological parameters were measured from 
arbitrarily selected sections of the SEM images, using Ellipse software (Version 2001; 
ViDiTo, Kosice, Slovak Republic). The distribution of the fiber diameters and pore sizes 
were determined quantitatively from 200 measurements. 
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3.1.5 Cell cultivation and seeding 
The mouse 3T3 fibroblast cells (line 3T3-Swiss albino CCL-92™, ATCC, 
Manassas, VA, USA) were routinely maintained in a humidified incubator (Shellab SS-
2306; Sheldon Manufacturing, Inc., Cornelius, OR, USA) with an atmosphere of 5% 
CO2 in air at 37°C with fresh medium added every 2 days. Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; PAN-Biotech GmbH, Aidenbach, 
Germany) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories GmbH, 
Pasching, Austria) and penicillin/streptomycin (100 IU/ml and 100 μg/mL, respectively, 
Sigma-Aldrich, St. Louis, MO, USA). When the cells reached 80-90% confluence they 
were suspended using Trypsin–Ethylenediaminetetraacetic acid (EDTA; PAA 
Laboratories GmbH, Pasching, Austria). The number of cells was determined using 
light microscopy. To detect the metabolic activity, proliferation and viability, fibroblasts 
were seeded on the scaffolds at a density of 3×103 cells/cm2, and to determine cell 
adhesion at a density of 3×104 cells/cm2, respectively. To eliminate any contribution 
from non-adherent cells, each scaffold was transferred to a new well on the plate 
before any in vitro tests. From each well, which contained 300 µL of medium, a volume 
of 150 µL of the medium was exchanged every second day. 
3.1.6 Cell adhesion by DiOC6 staining 
Staining with a 3,3’-Dihexyloxacarbocyanine iodide (DiOC6; Invitrogen, Carlsbad, 
CA, USA) fluorescent probe was used to detect adhesion of cells on the scaffolds. 
Samples were fixed with frozen methyl alcohol (–20˚C) for 10 min, and were rinsed 
with PBS followed by DiOC6 (0.1-1 μg/mL in PBS, pH 7.4). After 45-min incubation at 
RT, the samples were rinsed with PBS (pH 7.4), and propidium iodide (5 μg/mL in PBS, 
pH 7.4) was added for 10 min, rinsed with PBS (pH 7.4) again and visualized using a 
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Zeiss LSM 5 DUO confocal microscope (Zeiss, Oberkochen, Germany; λexc = 484 nm 
and λem = 482–497 nm). The areas of adhered cells were counted with Ellipse software 
(Version 2001; ViDiTo, Kosice, Slovak Republic). For each scaffold, an area of 100 
cells was measured and averaged.  
3.1.7 Cell metabolic activity analysis by the MTT test 
Cell metabolic activity was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) test. MTT (50 μL, 1 mg/mL; Sigma-Aldrich, St. 
Louis, MO, USA) in PBS (pH 7.4) was added to 150 μL of the sample medium and was 
incubated for 4 hours at 37°C. Using mitochondrial dehydrogenase of normally 
metabolizing cells, the MTT was reduced to purple formazan. The formazan crystals 
were solubilized with 100 μL of 50% N,N-dimethylformamide in 20% sodium dodecyl 
sulphate (SDS) at pH 4.7. The results were examined by spectrophotometry in an 
absorbance microplate reader (ELx800; BioTek, Winooski VT, USA) at 570 nm 
(reference wavelength 690 nm). The metabolic activity of 3T3 fibroblasts on a scaffold 
was tested on days 1, 3, 7, 10 and 14. 
3.1.8 Cell proliferation analysis by PicoGreen® assay 
The second proliferation analysis was carried out using the Invitrogen 
PicoGreen® assay kit (Quant-iT™ PicoGreen® dsDNA Reagent kit, Invitrogen, 
Carlsbad, CA, USA). The proliferation of 3T3 fibroblasts on the scaffolds was tested 
on days 1, 3, 7, 10 and 14. To process the material for an analysis of the DNA content, 
each scaffold was replaced in a vial with 500 μl of cell lysis solution (0.2% v/v Triton X-
100, 10 mM Tris (pH 7.0), 1 mM EDTA). To prepare the cell lysate, the samples were 
processed through a total of three freeze/thaw cycles; the scaffold sample was first 
frozen at -70 °C and thawed at RT. Between each freeze/thaw cycle, the scaffolds 
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were roughly vortexed. The prepared samples were stored at -70 °C until analysis. To 
quantify the cell number on the scaffolds, a cell based standard curve was prepared 
using samples with a known number of cells (range 100 – 5×105 cells). The DNA 
content was determined by mixing 100 μL PicoGreen reagent and 100 μL of the DNA 
sample. The samples were loaded in triplicate and the florescence intensity was 
measured on a multi-mode microplate reader (Synergy HT; BioTek, Winooski VT, 
USA; λex = 480–500 nm, λem = 520 – 540 nm).  
3.1.9 Viability of cells seeded on scaffolds by live/dead staining 
To detect cell viability, live/dead cell staining was performed. The cell viability of 
3T3 fibroblasts on the scaffold was tested on days 1, 3, 7, 10, 14. The cells were 
stained with 2´,7’-Bis[2carboxyethyl]-5[6]-carboxyfluorescein acetoxymethyl ester 
[(BCECF-AM), storage solution 1 mg/mL in dimethyl sulfoxide (DMSO)], and were 
finally diluted 1:100 in a serum-free medium; (Sigma-Aldrich, St. Louis, MO, USA) and 
propidium iodide (5 μg/mL in PBS, pH 7.4; Sigma-Aldrich, St. Louis, MO, USA). 
BCECF-AM was added to the scaffolds and incubated for 45 min at 37°C and 5% CO2 
and subsequently rinsed in PBS (pH 7.4). After rinsing with PBS (pH 7.4), propidium 
iodide was added for 10 min, then the scaffolds were rinsed again with PBS (pH 7.4) 
and visualized using a Zeiss LSM 5 DUO confocal microscope (BCECF - AM λex = 488 
nm and λem = 505–535 nm, propidium iodide λex = 543 nm and λem = 630–700 nm). 
BCECF-AM is an intracellular fluorescent pH indicator, which is hydrolysed to BCECF 
by cytosolic esterases. Thus, only live cells contribute to the staining results (green 
colour). Propidium iodide binds to double stranded DNA, but it can only cross the 
plasma membranes of non-viable cells (red colour). For each scaffold, the number of 
live/dead cells was counted with Ellipse software (Version 2001; ViDiTo, Kosice, 
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Slovak Republic) and was averaged. Viability was calculated as the percentage of live 
cells from the total cell count per unit area.  
3.1.10 Cell proliferation analysis by colorimetric immunoassay 
The proliferation activity of 3T3 fibroblasts seeded on the scaffolds was 
determined using a colorimetric immunoassay based on measurements of 5-bromo-
2’-deoxyuridine (BrdU), which is incorporated during DNA synthesis (Cell proliferation 
ELISA, BrdU, colorimetric; Roche Applied Science, Penzberg, Germany). The assay 
was performed according to the manufacturer’s instructions. Briefly, on days 1, 3, 7, 
10 and 14, each scaffold 100 µL BrdU-labeling solution was added to each well 
containing a scaffold and was allowed to incorporate into the cells in a CO2-incubator 
at 37°C for 2 h. Subsequently, the supernatant in each well was removed, and the 
scaffolds were incubated with FixDenat solution to fix the cells and denature the DNA 
at room temperature (RT) for 30 min. The supernatant was removed and, 
subsequently, 100 µL anti-BrdUperoxidase (dilution ratio = 1:100) was added and kept 
at RT for 60 min. After removing the unbound antibody conjugate, 100 µL of substrate 
solution was added, allowed to stand for 4 min, and the reaction was completed by 
adding 25 µL of H2SO4 solution (1M). Then, 100 µL of the solution was transferred to 
a 96-well plate and measured within 5 min at 450 nm with a reference wavelength of 
690 nm, using an absorbance microplate reader (ELx800; BioTek, Winooski VT, USA). 
The blank corresponded to a scaffold without cells, with or without BrdU. 
3.1.11 Statistical analysis of in vitro tests 
Quantitative data are presented as mean ± standard deviation (SD). For the in 
vitro tests, average values were determined from four independently prepared 
samples. The results were evaluated statistically, using One Way Analysis of Variance 
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(ANOVA) and the Student-Newman-Keuls Method. The level of significance was set 
at 0.001 and 0.05. 
3.2 In vivo testing of the composite scaffold based on a 
polypropylene surgical mesh functionalized with PCL 
nanofibers and adhered synthetic growth factors on a 
rabbit model 
3.2.1 Preparation of the functionalized scaffolds and composite 
meshes 
Preparation of the scaffold based on the polypropylene surgical mesh 
functionalized with PCL nanofibers is described in chapter 3.1.1. 
For in vivo tests on a rabbit model PCL nanofibers, Prolene™ (PP) and P coated 
with PCL nanofibers were cut into rectangular shape with 4 cm and 8 cm sides. The 
scaffolds were sterilized using ethylene oxide at 37°C. The synthetic GF were bound 
to the scaffold by 12h incubation in a PBS (pH 7.4) solution, which contained 200 
ng/mL IGF-I [human recombinant (hr), Sigma-Aldrich, St. Louis, MO, USA], 40 ng/mL 
bFGF (hr, Roche Applied Science, Penzberg, Germany), and 4 ng/mL TGF-2 (from 
porcine platelets, Sigma-Aldrich, St. Louis, MO, USA). After incubation GFs were 
adhered on the surface of nanofibers. The release of synthetic growth factors from 
nanofibers were in the order of 1 to 3 weeks (Filova E. et al. 2013). Implanted scaffolds 
without the GF were incubated in PBS (pH 7.4) for 12h.  
3.2.2 Rabbit animal model, study groups and animal care 
A total of 27 rabbits were randomly divided into six groups. In Group I (the control 
group), the tissue defect in the fascia was primarily closed using a 4/0 PP suture. In 
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Groups II, III and V, the defect in the fascia was closed with a 4/0 PP suture, a 4×8 cm 
mesh was placed over the fascia in an onlay position, overlapping the incision by 2 cm 
circumferentially. Group II was treated with a PP mesh only (the second control group), 
while Group III was treated with a PP mesh functionalized with PCL nanofibers 
enriched with GF, and Group V was treated with a PP mesh functionalized with PCL 
nanofibers without GF. The mesh was then fixed with a continuous suture technique, 
using a 4/0 PP suture. The last continuous stitch was used to suture the mesh to the 
incision line. Groups IV and VI were treated with PCL nanofibers only, with adhered 
GF (Group IV) or without GF (Group VI). For better understanding, the groups are 
summarized in Table 3.  











Abbreviations: PP, polypropylene; PCL, poly--caprolactone. 
Twenty seven Chinchilla rabbits (3.2±0.3 kg), 4 months old, were obtained from 
a conventional breed (CB Bio, Prague, Czech Republic) and bred in standard cages 
without bedding. The rabbits were fed ad libitum using the standard granular diet for 
rabbits (TM–MaK 1, Bergman, Karlovy Vary, Czech Republic). The Ethical Principles 
and Guidelines for Scientific Experiments on Animals were respected throughout this 
study. The maintenance and handling of the experimental animals followed EU Council 
Group Description 
I Suture only 
II PP 
III PP + PCL nanofibers + Growth Factors 
IV PCL nanofibers + Growth Factors 
V PP + PCL nanofibers 
VI PCL nanofibers 
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Directive (86/609 EEC), and the animals were treated in accordance with the principles 
of Care and Use of Animals.  
3.2.3 Surgical procedure, euthanasia and sample collection 
The animals were pre-medicated with intramuscular 15 mg Diazepamum pro toto 
(posteriorthigh – semitendinous and semimembranous muscles). The surgical 
procedure was conducted under general anesthesia using Ketamine (35 mg/kg) and 
Xylazine (3 mg/kg) and subsequently inhalation of O2 + 1.5-2.0% Halothane during 
surgery. Following completion of all the preoperative preparations, a skin incision of 
about 6 cm was cut through the midline of the abdomen, starting 3 cm below the 
xyphoid. Another 5 cm long midline incision was made in the fascia as an abdominal 
closure model. Antibiotics (20 mg/kg/day s.c. of Cefalexinum monohydricum, Cefalexin 
ad us. vet.) and analgesics (0.1mg/kg/day s.c. of Butorphanol tartrate) were 
administered during the first 3 days. The rabbits were not limited in their movement 
after surgery. The animals were euthanized using T61 (Schering-Plough Corporation, 
Kenilworth, NJ, USA) 6 weeks later.  
Samples for histological and immunohistochemical analysis were fixed in 10% 
phosphate-buffered formalin for 48 h. Two samples of 1×6 cm of full layer abdominal 
wall with mesh were removed for biomechanical testing (Figure 16), two samples from 
the suture line and two from the edge of the mesh were harvested for histological 














Figure 16. Full layer regenerated abdominal wall for biomechanical and histological analyses. (A) 
Incision of abdominal wall closed with PP mesh, (B) incision of abdominal wall closed with simple 
suture.  
Abbreviations: PP, polypropylene. 
3.2.4 Video-recorded biomechanical assay (tensile strength) 
The hysteresis curve and the maximum tensile strength were determined on a 
Micro tester digital tension meter (the device was developed in Department of Anatomy 
and Biomechanics, Faculty of Physical Education and Sport, Charles University in 
Prague, Utility model with document/registration number 25008, Industrial Property 
Office, Czech Republic). The structure of each sample was scanned throughout the 
experiment by an Olympus SZX-12 microscope (Olympus Corporation, Tokyo, Japan) 
equipped with an ultrasensitive SensiCam video camera (PCO, Kelheim, Germany). 
The force response of each sample was detected at the branches of the tension meters 
during the whole cycle. Both static and dynamic properties of each of the samples were 
analysed. The following quantities were measured: elasticity in traction E [N/mm2], 
maximum strength force σmax. per square unit [N/mm2] and the corresponding 
proportional elongation value εmax.. The localization and the character of the tear line 
were also analysed. The tissue samples (1×6 cm strips of regenerated abdominal wall) 
were individually attached to the branches of the tension meter in longitudinal manner, 
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not including the place covered with scaffolds of a particular type (Figure 17). The 
samples were stretched by 5 mm at a speed of 10 mm/s ten times and were then pulled 









Figure 17. Tensiometer branches with anchored samples during biomechanical analyses. 
3.2.5 Histological evaluation 
The tissue samples were fixed with buffered formalin, dehydrated and embedded 
in paraffin blocks. Six serial histological sections 5 µm in thickness were processed 
from each paraffin-embedded tissue block. α-Smooth muscle actin was used as a 
marker of the contractile SMC phenotype and myofibroblasts, and CD31 was used as 
an endothelial marker (Table 4). Endogenous peroxidase activity was blocked with 3% 
H2O2 in PBS. Non-specific binding activity was blocked with normal goat or horse 
serum (Table 4) in a phosphate-buffered salt solution at room temperature. The 
sections were incubated overnight with primary antibodies (Table 4) at 4°C. 
Immunoreaction products were detected using the immunoperoxidase technique 
(Table 4), and the reactions were visualized with diaminobenzidine (Sigma-Aldrich, St. 
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Louis, MO, USA). All sections were counterstained with Gill’s hematoxylin (Dr. Kulich 
Pharma, Otrokovice, Czech Republic). Quantification of area fractions of tissue 
constituents and quantification of microvessel density were done using stereological 
point counting method (Mouton P.R., 2002) and the unbiased counting frame provided 
by Ellipse software (ViDiTo, Kosice, Slovak Republic). 
Table 4. Primary antibodies used for immunohistochemistry 
Antibody Blocking serum Pre-treatment Detection 
Monoclonal Mouse Anti-
Human Smooth Muscle 




Normal goat serum 
(DakoCytomation) in 
PBS at room 
temperature 




Human and Anti-Rabbit 
CD31, Clone JC/70A 
(Vector Laboratories Ltd., 
Peterborough, UK) Dilution 
1:25 
(endothelial marker)  
Normal horse serum 




with Proteinase K 
(DakoCytomation) 
for 6 min 
ImmPress reagent kit 




3.2.6 Histological scoring system 
In the literature, there are no references to a method for comparing histological 
evaluations related to incisional hernia examinations. We suggest a novel scoring 
system, which is described in detail below.  
Two tissue blocks were examined in each animal, one representing the medial 
region of the abdominal wall with the healing incision, and the other approx. 20 mm 
laterally to the median incision. Six serial histological sections 5 µm in thickness were 
processed. Two sections were stained with hematoxylin-eosin (Merck KGaA, 
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Darmstadt, Germany), two sections were stained with Verhoeff’s hematoxylin (Merck 
KGaA, Darmstadt, Germany) and green trichrome (DiaPath, Martinengo, Italy) to 
visualize the connective tissue (Kocova J., 1970), and two sections were processed 
immunohistochemically in order to reveal the presence of micro vessels, smooth 
(SMC) and myofibroblasts. We used α-smooth muscle actin as a marker of the 
contractile SMC phenotype and myofibroblasts, and CD31 as an endothelial marker. 













Figure 18. Histological quantification. (A) In sections stained with Verhoeff’s hematoxylin (Merck 
KGaA, Darmstadt, Germany) and green trichrome (DiaPath, Martinengo, Italy), the area fraction of 
collagen (stained green), adipose tissue, and granulomatous infiltrates (red arrow) was quantified. 
The area occupied by dissolved tissue scaffolds (asterisk) or by artificial microcracks (black arrow) 
was excluded from the reference area. (B) For all area quantifications, stereological point grids were 
superimposed on histological micrographs, points striking the structures of interest within the total 
area were counted, and the sum of these points was multiplied by the area corresponding to each 
point (marked “a” within the square). This is illustrated in an immunohistochemical section showing 
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α-smooth muscle actin-positive vascular smooth muscle cells (yellow arrow) and myofibroblasts 
(green arrow). (C) Counting CD31-positive microvessel profiles per section area using projection of 
an unbiased counting frame consisting of two admittance borders (green) and two forbidden borders 
(red). (B,C) Counterstaining Gill’s hematoxylin (Dr. Kulich Pharma, Otrokovice, Czech Republic).  
Notes: (A) magnification × 100, scale bar 200 µm. (B,C) magnification × 200, scale bar 100 µm. 
We used five continuous variables describing the tissue reaction of the 
connective tissue below the dermis and superficial to the abdominal muscle. The 
presence of collagen, adipose tissue and granulomatous infiltrates was assessed in 
the sections stained with Verhoeff’s hematoxylin and green trichrome (Figure 18A). 
The presence of α-smooth muscle actin and the presence of CD31-positive micro 
vessel profiles were assessed in immunohistochemical sections (Figure 18B and C). 
Two micrographs for each staining and tissue block were taken in a systematic random 
manner, using a 20× objective (quantification of CD31-positive microvessels) or a 10 
× objective (other parameters). Next, a randomly positioned uniform grid of equidistant 
points was placed on the micrographs in an overlay, so that the number of points 
striking the collagen, adipose tissue, granulomatous infiltrates and α-smooth muscle 
actin-positive cells was proportional to their area. We counted the number of points 
striking these structures within the area of the abdominal scar. The area of each major 
tissue component A was calculated by multiplying the number of counted points by the 
area corresponding to each point (Gundersen H.J., 1978). The presence of each tissue 
component in the study was then expressed as their area fraction (AA) within the 
connective tissue of the scar and abdominal wall. The area not occupied by connective 
tissue (tissue micro cracks, dissolved mesh and surgical stitches, borders of the 
section) was excluded from the reference area. The sum of the area fraction of 
collagen, adipose tissue, granulomatous infiltrates and α-smooth muscle actin 
represents the main tissue constituents. The remaining fraction of the tissue was 
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occupied mostly by fibroblasts and scattered connective tissue cells, individual skeletal 
muscle fibers, ground substance of the extracellular matrix, immature collagen, and 
lumina of blood and lymphatic vessels. In sections stained for the α-smooth muscle 
actin and CD31, we assessed the quantity of micro vessels as the number of micro 
vessel profiles per section area QA, using an unbiased counting frame (Gundersen 
H.J., 1978). Although the α-smooth muscle actin did not label the capillaries which are 
lacking smooth muscle cells, we found a strong positive correlation (Spearman 
R=0.91) between the micro vessels labelled with α-smooth muscle actin and CD31-
positive micro vessels in a pilot study based on 12 tissue samples. Due to a stronger 
immunohistochemical reaction, we decided to consider the number of α-smooth 
muscle actin-positive micro vessels as an acceptable estimate for the presence of 
micro vessels. In total, the quantification was based on 220 micrographs. An estimate 
was made of the density of the micro vessel profiles, and 117 micro vessel profiles per 
sample were counted on an average. 
3.2.7 Statistical analysis for in vivo tests 
The quantitative histological data were processed using Statistics Base 9 
(StatSoft Inc., Tulsa, OK, USA). The Spearman rank order correlations were used as 
a measure of the statistical relations between the variables, and Kruskal-Wallis 
ANOVA was used for testing the equality of the population medians between the 
groups under study. We used the Wilcoxon matched pairs test for paired samples of 
the medial and lateral abdominal wall of the same animals. Values were considered 
statistically significant for p < 0.05. Only significant findings and findings close to 
significant values are reported.  
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3.3 In vivo testing of the scaffold based on PCL nanofibers 
functionalized with adhered human platelets on a 
minipig model.  
3.3.1 Preparation of the functionalised scaffolds 
Preparation of the PCL nanofibrous scaffolds is described in the chapter 3.1.1. 
For in vivo tests on a minipig model PCL nanofibers, PCL nanofibers with adhered 
human platelets or suture alone were used. Nanofibrous scaffolds were cut into a 
rectangular shape with sides of 4 cm and 9 cm. The scaffolds were sterilized using 
ethylene oxide at 37°C. TRS was prepared from human platelets in plasma (volume 
283 mL, platelets concentration 100x107 platelets/mL) as described in the chapter 
3.1.2. Final washed platelets pellet was resuspended in 50 mL of resuspendation 
buffer. The final concentration of platelets in TRS was 1x109. PCL scaffolds designated 
for functionalization were immersed in TRS for 2 hours to enable adhesion of platelets 
(Figure 12; Jakubova R. et al., 2011). After the incubation time, non-adhered platelets 
were removed by rinsing twice in PBS (pH 7.4). Scaffolds without adhered platelets 
were incubated in PBS (pH 7.4) for 2 h. Growth factors were released from the platelets 
adhered to the nanofibers over a period of 1 - 14 days (Buzgo M. et al., 2013). 
3.3.2 Minipig animal model, study groups and animal care 
The total of 10 male minipigs was randomly divided into two groups. For the 
implantation, the PCL nanofibers, PCL nanofibers with adhered human platelets (PCL 
nanofibers + TRS) or suture alone were used. Scaffold was placed over the fascia in 
an onlay position, overlapping the incision by 2 cm circumferentially. The scaffold was 
fixed with a continuous suture technique, using a 4/0 PP suture. The last continuous 
stitch was used to suture the mesh to the incision line. 
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10 male minipigs (19-31 kg), 6-8 months old, were obtained from a conventional 
breed (CB Bio, Prague, Czech Republic) and bred in standard individual boxes. The 
minipigs were fed with 1 kg of the standard complete feed mixture (A1, Cerea a.s., 
Pardubice, Czech republic). Quality controlled water was supplied ad libitum during the 
acclimatisation time and during the entire study period. The Ethical Principles and 
Guidelines for Scientific Experiments on Animals were respected throughout this study. 
The maintenance and handling of the experimental animals followed EU Council 
Directive (86/609 EEC), and the animals were treated in accordance with the principles 
of Care and Use of Animals.  
3.3.3 Surgical procedure, euthanasia and sample collection 
The animals were premedicated with Atropin (0.05 mg/kg, i.m.), Azaperon (2 
mg/kg, i.m.) and Ketamin (15 mg/kg, i.m.). After sedation, the animal was intubated. 
During the surgery, the anaesthesia was keeping by O2 + 1.5-2.0% Halothane 
inhalation. After ensuring a venous access entry with a catheter into the marginal ear 
vein, a 0.9% saline solution was supplied.  
After entering to anaesthesia, the animal was placed to the dorsal location. Its 
skin was shaved. The surgery site was disinfected with povidone-iodine (Braunol, 
B.Braun, Melsungen, Germany). Following completion of all the preoperative 
preparations, a four skin incision of about 8 cm was cut laterally from the nipples in 
particular quadrant of the abdominal wall (Figure 19). Consequently the incision into 
the frontal fascia of rectus abdominis muscle with the fain immobilisation into the 
muscle was made (Figure 20). The incision was in the length of 5 cm. The scaffold was 
placed over the fascia in an onlay position according to the scheme. The numbering of 
the particular incision is presented in Figure 19. Experimental and control defects were 
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rotated in the position to avoid affection of the healing process due to the particular 
position in the abdominal wall. The scaffold was fixed with a continuous suture 
technique, using a 4/0 Vicryl suture. The last continuous stitch was used to suture the 
mesh to the incision line. The incisionin the group treated without any scaffold (the 
control group), the fascia tissue defect was primarily closed using a continuous suture 







Figure 19. Numbering scheme of particular incision in abdominal wall. Experimental and control 
defects were rotated in the position to avoid affection of the healing process due to the particular 
position in the abdominal wall. 
Antibiotics (20 mg/kg/day s.c. of Cefalexinum monohydricum, Cefalexin ad us. 
vet.) and analgesics (0.1mg/kg/day s.c. of Butorphanol tartrate ad us.vet.) were 
administered during the first 3 days. The minipigs were not limited in their movement 
after surgery.  
The animals in one experimental group were euthanized 6 weeks and in second 
group 12 weeks after surgery.   Euthanasia was realised using premedication of 
Azaperon (2 mg/kg, i.m.) + Ketamin (15 mg/kg, i.m.) and administration of T61 (10 ml 










Figure 20. Surgery of the minipigs abdominal wall. (A) Incision in the fascia of rectus abdominis muscle. 
(B) Fixation of the implanted PCL nanofiber mesh. 
Samples of 2×6 cm of full layer abdominal wall with scaffold for histological and 
immunohistochemical analysis were removed and fixed in 10% phosphate-buffered 
formalin for 48 h. All suturing material was explanted prior to all tests. 
3.3.4 Histological evaluation 
The tissue samples were fixed in 10% phosphate-buffered formalin, dehydrated 
and embedded in paraffin blocks. The samples were prepared to represent the places 
of incision, as well as the abdominal wall approx. 20 mm apart from the incision. Eight 
serial histological sections 5 µm in thickness were processed from each paraffin-
embedded tissue block. Two sections were stained with haematoxylin-eosin, two 
sections were stained with Verhoeff’s haematoxylin and green trichrome (Kocova J., 
1970) to visualize the connective tissue, two sections were stained with picrosirius red 
(Direct Red 80, Sigma Aldrich, Munich, Germany) diluted in saturated picric acid 
solution for one hour to  visualize the type I collagen. The other two sections were 
processed immunohistochemically in order to reveal the presence of microvessels, 
SMC and myofibroblasts. We used α-smooth muscle actin as a marker of the 
contractile SMC phenotype and myofibroblasts. Endogenous peroxidase activity was 
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blocked with 3% H2O2 in PBS. Any unspecific binding activity was blocked with normal 
goat or horse serum in phosphate-buffered salt solution at room temperature. The 
sections were incubated overnight with monoclonal mouse anti-human smooth muscle 
actin primary antibody (dilution 1:1000, clone 1A4, DakoCytomation, Glostrup, 
Denmark) at 4°C. The products of the immunoreaction were detected using the 
immunoperoxidase technique (N-Histofine kit, Nichirei Biosciences, Tokyo, Japan) and 
the reactions were visualized with diaminobenzidine (Fluka, Buchs, Germany). All the 
sections were counterstained with Gill’s haematoxylin. 
All quantitative estimates were done using well established stereological methods 
(Mouton P.R., 2002) and the Ellipse software (ViDiTo, Košice, Slovakia). The new 
scoring system used in both in vivo studies is described in chapter 3.2.6 in more detail. 
We used six continuous variables describing the tissue reaction of the connective 
tissue below the dermis and superficial to the abdominal muscle fascia. The presence 
of type I collagen was assessed in sections stained with picrosirius red using the 
circularly polarized light. The advantages of this method were described by Rich and 
Whittaker (Rich L. and Whittaker P., 2005). The picrosirius red enhances the 
birefringence of co-aligned type I collagen fibrils and fibres. This phenomenon can be 
used for reproducible morphological quantification of the type I collagen content with 
high specificity and sensitivity (Junqueira L.C. et al., 1979). According to the thickness, 
type I collagen fibres appear in yellow (thinner fibres), orange, and red colour (thick 
bundles of fibres). The presence of α-smooth muscle actin-positive cells was quantified 
in immunohistochemical sections.  
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3.3.5 Statistical analysis for in vivo tests 
The data were processed with the Statistica Base 9 (StatSoft, Inc., Tulsa, OK, 
USA). As a measure of the statistical relations between the variables, the Spearman 
rank order correlations were used. Kruskal-Wallis ANOVA and the Mann Whitney U 
test were used for testing the equality of population medians between the groups under 
study. For paired samples with and without incision in the same animals, we used the 
Wilcoxon matched pairs test. Values were considered statistically significant for p < 
0.05. Only significant findings and finding close to significant values are reported. 
3.4 In vitro testing of the scaffold base on cryogrinded PCL 
nanofibers with potential use as a drug delivery system 
for tissue engineering  
3.4.1 Preparation of the microspheres by cryogrinding of PCL 
nanofibers 
The complete preparation process of a potential drug delivery system based on 
microspeheres derived from the PCL nanofibers by the cryogrinding technique was 
comprehensively described in our group by Knotek et al. (Knotek P. et al., 2012). 
Briefly, the PCL nanofibers prepared by a needleless electerospinning method were 
pulverizing from deep frozen state in cryogenic impact grinder. The cryogrinding 
process was carried out in different supporting grinding media and, such as mannitol, 
Pluronic and 2-octanol. The particle size distribution and the morphology were 
analysed using Mastersizer 2000 MU (Malvern Ins., Malvern, United Kingdom) and 
SEM Jeol JSM 5500 LV (JEOL Ltd, Tokyo, Japan) respectively.  
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3.4.2 Cell cultivation and seeding 
For in vitro testing of cryogrinded microsphere, mouse 3T3 fibroblast were used. 
Exact procedure of cell cultivation is described in chapter 3.1.5. There were several 
modifications of the previously described method. Fibroblasts were seeded on the 
microsphere scaffolds at a density of 6×103 cells/cm2. Prior to seeding cells, the 
microsphere scaffolds (30 mg) were sterilized in 70% ethanol (v/v) for 30 min and put 
into each well of 96-well plate. In order to prevent cell from adhering to the well surface, 
wells were modified with 1% Pluronic-127. A 50 µl aliquot of the cell suspension was 
added into each well and incubated for 2 h. Then 150 μl of cell culture medium was 
added to the samples and cells were cultured at 37 °C in a humidified atmosphere with 
5% CO2. 
3.4.3 Cell adhesion on the microspheres by DiOC6 staining 
The complete procedure of cell adhesion evaluation by using the confocal 
microscopy and DiOC6 staining is described in the chapter 3.1.6. Cell adhesion was 
evaluated on microspheres cryogrinded in all three different supporting grinding media.  
3.4.4 Cell proliferation analysis by PicoGreen® assay 
The complete cell proliferative PicoGreen® assay is described in chapter 3.1.8. 
The proliferation of 3T3 fibroblasts on either PCL microspheres cryogrinded in mannitol 
supporting media or PCL nanofibers was evaluated on days 1, 7, 14 and 21.  
3.4.5 Cell metabolic activity analysis by the MTS test 
Cell metabolic activity was measured using the 3-[4,5-dimethylthiazol-2-yl]-(3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium bromid (MTS) test. Samples of either PCL microspheres cryogrinded in 
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mannitol supporting media or nanofibers on days 1, 7, 14 and 21 were transferred to a 
new 96-well plate containing 100 μl of fresh full medium per well and 20 μl of CellTiter 
96® Aqueous One Solution Reagent was added (CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay, Promega, Fitchburg, WI, USA). The formazan absorbance in 
100 μl of the solution was measured (λsample = 490 nm, λreference = 690 nm) after 2-h 
incubation at 37 °C and 5% CO2 using a microplate reader ELx800. The absorbance 
of the samples without cells was deducted from the cell-seeded samples. Values 











4.1 In vitro testing of the composite scaffold based on a 
polypropylene surgical mesh functionalized with PCL 
nanofibers and adhered human platelets 
4.1.1 SEM and stereological analysis of the scaffolds 
The functionalized mesh was prepared by attaching the PP mesh on to the 
collector before the electrospinning process. PCL nanofibers were deposited on the 
surface of the PP mesh. The PP mesh with nanofibers was exposed in an aqueous 
environment for 2 weeks without any visual effect on the functionalized mesh. Three 
types of functionalised scaffolds were examined using scanning electron microscopy 
in secondary electron mode. Samples of the PP mesh (Figure 21B) were functionalized 







Figure 21. SEM of the scaffolds. (A) PCL nanofibers, (B) PP mesh, (C) PP mesh functionalized with 
PCL nanofibers.     
Notes: (A) magnification × 230, scale bar 50 µm, (B,C) magnification × 18, scale bar 500 µm. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone. 
Scanning electron microscopy revealed a randomly-oriented nanofibers and their 
deposition onto the PP mesh. Stereological analyses divided the nanofibers into two 
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fractions of PCL fibers. The first fraction contained fibers with an average diameter of 
1.29 × 103±0.33 × 103 nm, while in the second fraction the average diameter was 
466±170 nm. The average diameter of the PP mesh fibers was about 150 × 103±5.4 × 
103 nm. This kind of system was therefore considered suitable for further cell studies. 
4.1.2 PCL nanofibers significantly improved cell adhesion and 
metabolic activity 
Functionalization of the PP mesh significantly improved the adhesion and the 
metabolic activity of the 3T3 fibroblasts.  
First, cell adhesion was evaluated 24 hours after seeding. 3T3 fibroblasts were 
stained using DiOC6 and propidium iodide, were visualised using confocal microscopy, 
and areas of the spread cell surface were measured. A significantly larger surface area 
of the cells was observed on the PP mesh functionalized with PCL nanofibers than on 
the PP mesh alone (Figure 22). In addition, the largest spreading area was for the cells 
cultivated on the PP mesh functionalized with PCL nanofibers and TRS. 
Simultaneously, enrichment of the PP mesh with TRS improved cell adhesion, and the 
cell spreading area of PP + TRS was significantly larger than for PP (p < 0.001). 
Clearly, PP meshes functionalized with PCL nanofibers alone, and also PP meshes 
treated with TRS, significantly improved 3T3 adhesion. These two effects seem to be 













Figure 22. Cell adhesion evaluated on the first day after seeding. Average surface area of spread 
3T3 fibroblasts cultivated on the surface of a PP mesh (1), a PP mesh  treated with TRS (2), a PP 
mesh functionalized with PCL nanofibers (3), a PP mesh functionalized with PCL nanofibers treated 
with TRS (4). A cell adhesion assay revealed a significantly larger surface area of spread 3T3 
fibroblasts on scaffolds functionalized with PCL nanofibers (PP + PCL and PP + PCL + TRS) than 
on scaffolds without functionalization (PP and PP + TRS). Moreover, the average surface area of 
3T3 fibroblasts was significantly higher (level of significance at a value of p < 0.001) on the PP mesh 
functionalized with PCL nanofibers treated with TRS than on all other scaffolds.  
Notes: The level of statistical significance for the assays is designated above the mean values (p < 
0.05 indicated by number, p < 0.001 indicated by number and *). Day 1: 2 ˃ 1*; 3 ˃ 1*, 2; 4 ˃ 1*, 2*, 
3*. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone; TRS, thrombocyte-rich solution; µm2, 
square micrometre.  
3T3 fibroblast metabolic activity was determined by the MTT assay. The MTT 
assay revealed significantly higher metabolic activity of the cells after the 10th day of 
cultivation on any composite scaffolds than on the PP mesh alone (Figure 23). 
Moreover, significantly higher (p < 0.001) metabolic activity of the cells was observed 
on any functionalized composite scaffolds on day 14. Significantly higher metabolic 
activity was also observed on either a PP mesh functionalized with PCL nanofibers or 
a PP mesh functionalized with PCL nanofibers treated with TRS after the 7th day of 
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cultivation. Additionally, a combination of two improvements, namely functionalization 
of the PP mesh with PCL naofibers and treatment with TRS, led to significantly higher 









Figure 23. Metabolic activity of 3T3 fibroblasts cultivated on the surface of a PP mesh (1), PP mesh 
enriched with adhered thrombocytes (2), PP mesh functionalized with PCL nanofibers (3), PP mesh 
functionalized with PCL nanofibers enriched with adhered thrombocytes (4). The MTT assay 
revealed significantly higher metabolic activity of 3T3 fibroblasts on scaffolds functionalized with PCL 
nanofibers (PP + PCL and PP + PCL + TRS) on day 14 than on scaffolds without functionalization 
(PP). Moreover, the metabolic activity of 3T3 fibroblasts on days 7, 10 and 14 was significantly higher 
on the PP mesh functionalized with PCL nanofibers treated with TRS than on all other scaffolds.  
Notes: The level of statistical significance for the assays is designated above the mean values (p < 
0.05 indicated by a number, p < 0.001 indicated by a number and *). Day 1: without significance. Day 
3: 3 > 1, 2; 4 ˃ 1*, 2*. Day 7: 3 ˃ 1; 4 ˃ 1*, 2*, 3. Day 10: 2 ˃ 1; 3 ˃ 1*; 4 ˃ 1*, 2, 3. Day 14: 2 ˃ 1*; 3 
˃ 1*, 2*; 4 ˃ 1*, 2*, 3. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone; TRS, thrombocyte-rich solution; MTT, 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; AU, absorbance units. 
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4.1.3 Increased metabolic activity is accompanied by a larger 
number of cells 
The increase in the number of cells, which is the result of good proliferation, was 
estimated from the DNA values measured using a PicoGreen assay (Figure 24). The 
results of the Picogreen assay on days 1, 3, 7, 10, and 14 clearly indicated substantial 
cell proliferation on the functionalized scaffolds. A significantly higher number of cells 
were observed on days 10 and 14 on any composite scaffold than on the PP mesh 
alone. Additionally, the PicoGreen assay confirmed a significantly larger number of 
cells (p < 0.001) on the scaffold with the most advanced improvement, ie the PP mesh 
functionalized with PCL nanofibers treated with TRS on days 10 and 14 than on all 
other scaffolds that were investigated. These results are consistent with the results for 







Figure 24. Proliferative activity of 3T3 fibroblasts cultivated on the surface of a PP mesh (1), PP 
mesh enriched with adhered thrombocytes (2), PP mesh functionalized with PCL nanofibers (3), PP 
mesh functionalized with PCL nanofibers treated with TRS (4). The PicoGreen assay revealed 
significantly higher proliferation of 3T3 fibroblasts on scaffolds functionalized with PCL nanofibers 
(PP + PCL and PP + PCL + TRS) on days 7, 10 and 14 than on scaffolds without functionalization 
(PP and PP + TRS). In addition, the proliferation of 3T3 fibroblasts on days 7, 10 and 14 was 
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significantly higher (level of significance at value of p < 0.001) on the PP mesh functionalized with 
PCL nanofibers enriched with adhered thrombocytes than on all other scaffolds.  
Notes: The level of statistical significance for the assays is designated above the mean values (p < 
0.05 indicated by a number, p < 0.001 indicated by a number and *). Day 1: 4 > 1, 2, 3. Day 3: 3 > 
1, 2; 4 > 1, 2. Day 7: 3 > 1, 2; 4 > 1*, 2*, 3*. Day 10: 2 > 1*; 3 > 1*, 2*; 4 > 1*, 2*, 3*. Day 14: 2 > 1; 
3 > 1*, 2; 4 > 1*, 2*, 3*. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone; TRS, thrombocyte-rich solution. 
However the concentration of cells does not reflect the ratio of live and dead cells, 
so a live/dead cell staining assay was performed. The viability of the 3T3 fibroblasts 
was evaluated on days 1, 3, 7, 10, 14 after seeding. For the simplification only data 
obtained on day 14 are presented (Figure 25). Live cells were stained by BCECF-AM 
(green colour) and by propidium iodide (red). Viability was calculated as the 










Figure 25. Viability of 3T3 fibroblasts cultivated on the surface of a PP mesh (A), a PP mesh treated 
with TRS (B), a PP mesh functionalized with PCL nanofibers (C), a PP mesh functionalized with PCL 
nanofibers treated with TRS (D), PCL nanofibers (E), PCL nanofibers treated with TRS (F) on day 
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14 after seeding. Live/dead cell staining revealed a higher percentage of viable cells on all scaffolds 
functionalized either with PCL nanofibers or with TRS than on the scaffold without any 
functionalization or treatment (PP). The percentage of viable cells cultivated on the surface of 
scaffold A was: 59,5%, B: 85,4%, C: 88,3%, D: 90,1%, E: 90,3%, F: 94,7%. 
Notes: The viability of 3T3 fibroblasts was evaluated on days 1, 3, 7, 10, 14 after seeding. For the 
simplification only data obtained on day 14 are presented. Viability was calculated as the percentage 
of live cells from the total cell count per unit area. Live cells are stained green. Dead cells are stained 
red. Scale bar 200 µm. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone. 
Live/dead cell staining revealed a higher percentage of viable cells in all scaffolds 
either functionalized with PCL nanofibers or treated with TRS than on a PP mesh 
alone. In particular, the percentage of viable cells on the PP mesh treated only with 
TRS was 85.4%, on the PP mesh functionalized with PCL nanofibers the value was 
88.3%, and the PP mesh functionalized with PCL nanofibers treated with TRS showed 
90.1% of viable cells. In the two control groups, the percentage of viable cells was 
90.3% for the cells seeded on PCL nanofibers alone, and 94.7% for the cells seeded 
on PCL nanofibers treated with TRS. Previous results confirmed the conclusion that a 
PP mesh enriched with either PCL nanofiber functionalization or with TRS treatment 
improved 3T3 fibroblast viability. 
4.1.4 Functionalization of the PP mesh also improved cell 
proliferation significantly. 
Cell metabolic activity can result not only in a larger number of cells, as was 
confirmed by our study of DNA content, but also in cell proliferation. Cell proliferation 
was therefore evaluated using a BrdU colorimetric immunoassay. This assay is based 
on incorporating bromodeoxyuridine only in the active process of DNA synthesis in 
healthy cells. A BrdU colorimetric immunoassay was performed on days 1, 3, 7, 10 and 
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14 (Figure 26). The BrdU assay revealed significantly higher proliferation of 3T3 
fibroblasts on scaffolds functionalized either with PCL nanofibers or with PCL 
nanofibers treated with TRS on all evaluation days than on scaffolds without 
functionalization, namely the PP mesh alone and the PP mesh treated with TRS. 
Moreover, the proliferation of 3T3 fibroblasts on day 14 was significantly higher (p  
0.001) on the PP mesh functionalized with PCL nanofibers treated with TRS than on 
all other scaffolds. Polypropylene mesh functionalization also significantly improves 









Figure 26. Proliferation of 3T3 fibroblasts cultivated on the surface of a PP mesh (1), PP mesh 
treated with TRS (2), PP mesh functionalized with PCL nanofibers (3), PP mesh functionalized with 
PCL nanofibers treated with TRS (4). A BrdU colorimetric immunoassay revealed significantly greater 
proliferation of 3T3 fibroblasts on scaffolds functionalized with PCL nanofibers (PP + PCL and PP + 
PCL + TRS) on all days of evaluation than on scaffolds without functionalization (PP and PP + TRS). 
In addition, the proliferation of 3T3 fibroblasts on day 14 was significantly higher (p < 0.001) on the 
PP mesh functionalized with PCL nanofibers treated with TRS than on all other scaffolds.  
Notes: The level of statistical significance for the assays is designated above the mean values (p < 
0.05 indicated by a number, p < 0.001 indicated by a number and *). Day 1: 3 ˃ 1*, 2*; 4 ˃ 1*, 2*. 
Day 3: 3 ˃ 1*, 2; 4 ˃ 1*, 2*. Day 7: 3 ˃ 1*, 2*; 4 ˃ 1*, 2. Day 10: 3 ˃ 1*, 2*; 4 ˃ 1*, 2*, 3. Day 14: 2 ˃ 
1*; 3 ˃ 1*, 2; 4 ˃ 1*, 2*, 3*. 
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Abbreviations: PP, polypropylene; PCL, poly--caprolactone; TRS, thrombocyte-rich solution; 
BrdU, 5-bromo-2’-deoxyuridine; AU, absorbance units. 
4.2 In vivo testing of the composite scaffold based on a 
polypropylene surgical mesh functionalized with the 
PCL nanofibers and adhered synthetic growth factors on 
rabbits as a small animal model. 
4.2.1 Clinical postoperative course 
The animals were euthanized after 6 weeks. We did not observe any evident 
changes of condition or weight loss of any animal. A macroscopic evaluation of 
samples from all groups was made after explanation of abdominal wall (Figure 16). 
The surface of the regenerated tissue showed no signs of inflammation or infection in 
any groups. The incidence of hernia was not observed in any samples. 
4.2.2 Video-recorded biomechanical assay (tensile strength) 
The animals were sacrificed six weeks after surgery and samples of their 
abdominal wall, including the scar, mesh and healthy tissue were harvested. 1×6 cm 
strips of regenerated abdominal wall of each animal (Figure 16), as was described in 
Methods, were tested for hysteresis and maximum tensile strength, using a Micro 
tester digital tension meter (Figure 17). The tissue samples were individually attached 
to the branches of the tension meter in longitudinal manner, not including the place 
covered with scaffolds of a particular type. The samples were stretched by 5 mm at a 
speed of 10 mm/s ten times and were then pulled at a speed of 0.5 mm/s until the 
sample broke (Figure 27). The force response of each sample was detected, and both 
the static and the dynamic properties of each of the samples were analysed. Average 
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values of all measured data are summarized in Table 5.  
Figure 27. Video-recorded 
biomechanical assay (tensile 
strength). (A) Simple suture 
tears in the line. (B) Healthy 
muscle broke at the edge and 
the PP mesh slid on the top of 
the muscle. (C) Tissue treated 
by a PP mesh functionalized 
with PCL nanofibers enriched 
with adhered GF tore at the 
edge of the mesh and healthy 
muscle, and the slide was 
localized between muscle 
fibers. (D) In some PCL 
nanofiber samples with adhered 
GF, the suture line tore first, but 
in others a tear occurred 
between muscle fibers or at the 
edge of the muscle and the 
mesh. (E) Healthy muscle tore 
at the edge and a PP mesh 
functionalized with PCL 
nanofibers slid on top of the 
muscle, or the tear was 
localized not between the mesh 
and the muscle layer but in 
between muscle fibers. (F) In some PCL nanofiber samples, the suture line tore first, but in others a 
tear occurred between muscle fibers or at the edge of the muscle and the mesh. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone; GF, growth factors. 
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Values of the variables differed minimally among the groups, because the breach 
of the tear was almost unconditionally localized at the level of a muscle. The locations 
of the tear, however, varied significantly among the groups. The suture line broke first 
if it was not supported by any mesh. Thus, we have confirmed that the suture line is 
the weakest point of the abdominal wall 6 weeks post-surgery (Figure 27A). In all 
samples with the PP mesh, the tissue broke first at the edge of the mesh and healthy 
muscle followed by a slide of the PP mesh on top of a muscle (Figure 27B, C, E). The 
boundary of the mesh and the muscle created a stress concentration leading to the 
slip. 









Notes: Six experimental groups are presented in Methods and in Table1. 
Abbreviations: E, elasticity in traction or Young modulus in N/mm2 (MPa) ; σmax, average values of 
maximal strength force per square unit in N/mm2 (MPa); εmax, maximal proportional elongation value. 
In the group with PP functionalized with PCL nanofibers (Figure 27E), two types 
of tear mechanism were recorded. This was the same as in the PP mesh group, but in 
some samples the slide was localized not between the mesh and the muscle layer but 
in between the muscle fibers. In the group of PP mesh functionalized with PCL 
nanofibers enriched with adhered GF (Figure 27C), the tissue also tore at the edge of 
the mesh and the healthy muscle, and the slide was localized between muscle fibers, 
Group E [N/mm2] σmax [N/mm2] εmax [-] 
I 3.73 ± 1.21 0.50 ± 0.14 0.30 ± 0.04 
II 2.55 ± 0.75 0.46 ± 0.07 0.71 ± 0.16 
III 2.73 ± 0.20 0.61 ± 0.08 0.61 ± 0.06 
IV 2.60 ± 1.23 0.64 ± 0.10 0.61 ± 0.15 
V 2.78 ± 1.09 0.63 ± 0.04 0.65 ± 0.10 
VI 3.11 ± 1.43 0.68 ± 0.08 0.49 ± 0.08 
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with the exception of one sample, where the recorded mechanism was exactly the 
same as in the PP mesh group. The PCL nanofibers connected better to the abdominal 
wall than the PP mesh alone. 
In case of pure PCL nanofibers (Figure 27D and F), various types of tear were 
observed. In some samples the suture line tore first. In other samples a tear occurred 
between muscle fibers or at the edge of the muscle and the mesh.  
Static and dynamic parts of the experiment are documented in Table 5. We 
compared the average maximal strength force values. All samples functionalized with 
PCL nanofibers (Groups III – VI), with or without adhered GF, showed a significantly 
increased average maximal strength force (σmax.) compared to a simple PP mesh or 
suture (Groups I and II). Clearly, preserving the elasticity in traction and simultaneously 
increasing the maximum strength force value indicated a positive effect of nanofibers 
on fascia healing. Interestingly, PCL nanofibers alone (Group VI) showed the highest 
average maximal strength force value among all samples. Significant differences of 
average maximal strength force (σmax.) among the experimental groups are presented 
in Figure 28. 
Our results also indicated somewhat more elastic samples in the presence of the 
PP mesh (Groups II-V) compared to samples without the mesh (Groups I and VI), as 
indicated by their slightly lower Young's modulus. A significantly lower elasticity in 
traction (E) and higher elongation in Group IV (PCL nanofibers with growth factors) 
than in Group VI (PCL nanofibers without growth factors) indicated accelerated fascia 











Figure 28. Average values of maximal strength force per square unit in N/mm2 (MPa) after 6 weeks. 
Notes: The level of statistical significance for the measurement is indicated above the mean values:  
p < 0.05 indicated by *. 
Abbreviations: σmax, average values of maximal strength force per square unit; N, Newton; mm2, 
square millimetre; MPa, megapascal; PP, polypropylene; PCL, poly--caprolactone; GF, growth 
factors. 
4.2.3 Histological evaluation 
The implants were prepared and implanted as described in Methods, and were 
tested in vivo on a small animal model (a rabbit). The animals were sacrificed after 6 
weeks. In all groups of scaffolds there were some differences among the groups in the 
area fraction occupied by granulomatous infiltrate in medial samples taken from the 
healing incision, but the difference did not reach statistical significance (Figure 29A). 
Medial samples with the incision had a higher α-smooth muscle actin fraction 
(p=0.003), a lower collagen fraction (p=0.035) and a higher density of microvessels 

















Figure 29. Quantitative histological results. (A) Inflammatory infiltrate in the medial healing incision 
in group I (suture only), II (PP mesh), III (PP mesh functionalized with PCL nanofibers enriched with 
adhered GF), IV (PCL nanofibers enriched with adhered GF), V (PP mesh functionalized with PCL 
nanofibers) and VI (PCL nanofibers alone). (B) Fraction of α-smooth muscle actin positive vascular 
smooth muscle cells and myofibroblasts in the medial healing incision in groups I-VI (C) Density of 
microvessel profiles in medial healing incisions in groups I-VI. (D) Density of microvessel profiles in 
the abdominal wall 20 mm lateral from the incision in groups I-VI.  
Notes: The data are presented as medians with boxes spanning the upper limits of the first and third 
quartiles and with whiskers spanning the minimum and maximum values for each group. P-values of 
the Kruskal Wallis ANOVA show the differences among the groups under study. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone; GF, growth factors; Aa, area fraction; 
Qa, section area. 
 A considerable difference was observed in the area occupied by α-smooth 
muscle actin-positive cells in medial samples of the healing incision (Figure 29B). 
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There were more α-smooth muscle actin-positive cells in all samples containing PCL 
nanofibers than in the controls (simple suture and PP mesh) (Figure 30). There was 
no significant difference between the groups containing PCL nanofibers, with the 
exception of the samples from the lateral portion of the healing incision in PCL-only 
treated specimens.  
Significant differences in the density of the microvessel profiles were observed 
between the groups in both the medial and the lateral parts of the healing fascia (Figure 
29C and D). Samples containing PCL nanofibers had a greater density of microvessel 
profiles than the control groups (simple suture and PP mesh). The density was clearly 
highest in the lateral portion of samples with a PP mesh functionalized with PCL 
nanofibers enriched with adhered GF. 
PCL nanofiber scaffolds showed beneficial properties in fascia healing, and 
should be further tested in hernia repair application. From the histological point of view, 
the highest fraction of collagen was observed in samples with PCL nanofibers enriched 
with adhered GF, followed by samples with no mesh (incision) and by samples 
functionalized with PCL nanofibers (Figure 31). Samples functionalized with PCL 
nanofibers and enriched with adhered GF also contained low fractions of adipose 
tissue (Figure 31). The presence of PCL nanofibers and GF seemed to increase the 
granulomatous infiltration and vascularization of the healing tissue, because the 
remnants of nanofibers were surrounded by granulomatous leukocyte-rich connective 
tissue at the end of the sixth week after implantation. Tissue samples with heavier 
granulomatous infiltration also contained more blood vessels and a higher fraction of 




















Figure 30. α-smooth muscle positivity in the scaffolds under study. The density of the microvessels 
(some of them pointed with black arrows) and the area fraction of actin-positive cells (vascular 
smooth muscle and myofibroblasts, some of the accumulated myofibroblasts highlighted with blue 
arrows) were highest in the PP mesh samples functionalized with PCL nanofibers enriched with 
adhered GF (C), followed by the PP mesh functionalized with PCL nanofibers (E), PCL nanofibers 
(F) and PCL nanofibers enriched with adhered GF (D), while the lowest values were found in samples 
of pure PP meshes (B) and sham-operated animals with no mesh (A).  
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Notes: Immunohistochemistry for α-smooth muscle actin, counterstaining Gill’s hematoxylin. 
Magnification × 100, scale bar 200 µm. 

















Figure 31. Collagen, adipose tissue, and granulomatous infiltration in the scaffolds under study. In 
samples without any mesh (A), the incision was healing with a mixture of collagen (red arrow), 
adipose connective tissue (black arrow) and inflammatory infiltrate (yellow arrow). Samples with PP 
mesh (B) had a high fraction of adipose tissue, but the spaces showing the dissolved mesh (black 
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arrows) were surrounded by only a few inflammatory cells. Remnants of the nanofibers (C,D,E,F) 
were surrounded by granulomatous leukocyte-rich connective tissue (yellow arrows in C,D,E,F). The 
highest fraction of collagen (red arrow) was in samples of PCL nanofibers with adhered GF (D), 
followed by samples with no mesh (A) and by samples of PCL nanofibers (F). Low fractions of 
adipose tissue were found in samples of PCL nanofibers with adhered GF (D), samples with no mesh 
(A) and in samples of PCL nanofibers (F).  
Notes: Verhoeff’s hematoxylin and green trichrome staining. Magnification × 100, scale bar 200 µm. 
Abbreviations: PP, polypropylene; PCL, poly--caprolactone; GF, growth factors. 
The non-parametric Spearman rank order correlations between the quantitative 
histological parameters are listed in Table 6 (for this purpose, the data were pooled 
across all groups in the study). Tissue samples with heavier granulomatous infiltration 
contained more blood vessels and a higher fraction of vascular smooth muscle and 
myofibroblasts at the site of the healing incision. 
Table 6. The non-parametric Spearman rank order correlations between the quantitative parameters at 
the healing incision (medial side)/without incision (lateral side) 
 Aa (adipose) Aa (infiltrate) Aa (actin) Qa (microvessel)(mm-2) 
Aa (collagen) -0.59/-0.42 -0.46/-0.50 n.s./n.s. n.s./n.s. 
Aa (adipose) - n.s./n.s. n.s./n.s. n.s./n.s. 
Aa (infiltrate) - - 0.57/0.47 0.50/n.s. 
Aa (actin) - - - 0.53/0.69 
Notes: Marked correlations are significant at p < 0.05, other correlations did not reach statistical 
significance (n.s.). Autocorrelations and repeating values are replaced by a – sign. 




4.3 In vivo testing of a scaffold based on the PCL nanofibers 
functionalized with adhered human platelets on minipigs 
as a large animal model. 
4.3.1 Clinical postoperative course 
The animals were euthanized either after 6 or 12 weeks. We did not observe any 
evident changes of condition or weight loss of any animal during the entire study 
period. One animal underwent on day 14 a dehiscence of the surgical wound with an 
empyematic discharge. The edges of the wound were treated by curettage and 
carefully disinfected with povidone-iodine (Braunol). The wounds were stitched with 
absorbable surgical suture with a temporary drain. The animal was administred 
Amoxicillin-Clavulanate antibiotics (2.5 mL i.m., pro toto; Synulox® RTU, Pfizer Limited, 
Tadworth, UK). In other animals the post-operative condition was good. Wound healing 
went with no secondary complication or effect to the animal’s day activity, such as 
movement, liquid and food intake or excretion.   
4.3.2 Histological evaluation 
The samples contained several layers of subcutaneous fat, abdominal muscles 
and their fasciae, extraperitoneal fat, and the parietal peritoneum. The deep truncal 
fascia often contained remnants of elastic fibres. The total thickness of the abdominal 
wall varied considerably. Although some parts of the abdominal fasciae appeared to 
be merged, the layers of abdominal skeletal muscles usually kept their organization 




4.3.2.1 Differences between experimental groups 
Typical histological findings representing the groups under study are summarized 
in Figures 32, 33 and 34.  
Figure 32 shows the presence of collagenous connective tissue and adipose 
tissue. Nanofiber scaffolds were well integrated to the connective tissue. Their 
remnants were surrounded with granulomatous leukocyte-rich connective tissue mixed 
with dense collagenous connective tissue.  
In Figure 33 we can observe the lower fraction of α-smooth muscle-positive cells 
(vascular smooth muscle and myofibroblasts) in the samples with no scaffolds 
compared to the samples treated with either PCL nanofibers or PCL nanofibers with 
adhered platelets.  
Figure 34 shows the greater fraction of the type I collagen at the site without 




























Figure 32. Between-groups comparison and differences between the incision (left) and adjacent region 
20 mm apart from the healing incision (right), overall trichrome stain. In samples without any scaffold 
(A), the stitches were surrounded by collagenous connective tissue (red arrow) and adipose tissue 
(black arrow). The remnants of nanofibres (B,C) were well integrated to the connective tissue and 
surrounded with granulomatous leukocyte-rich connective tissue (yellow arrow) mixed with dense 
collagenous connective tissue (red arrow). In all groups, the abdominal wall without incision consisted 
mostly of truncal fascia and adipose tissue overlying the abdominal muscles.  
Notes: Verhoeff’s haematoxylin and green trichrome stain. Magnification × 100, scale bar 200 µm. 
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Figure 33. Between-groups comparison and differences between the incision (left) and adjacent region 
20 mm apart from the healing incision (right), α-smooth muscle actin immunohistochemistry. In samples 
without any scaffold (A), the fraction of α-smooth muscle-positive cells (vascular smooth muscle and 
myofibroblasts, some of the fraction pointed with blue arrows) was smaller than in samples with PCL 
nanofibres (B) and PCL nanofibres with TRS (C).  
Notes: Immunohistochemistry for α-smooth muscle actin showing positive myofibroblasts and vascular 
smooth muscle cells, counterstaining Gill’s haematoxylin. Magnification × 100, scale bar 200 µm. 
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Figure 34. Between-groups comparison and differences between the incision (left) and adjacent region 
20 mm apart from the healing incision (right), picrosirius red observed in circular polarization. In all 
groups under study (A-C), the fraction of type I collagen (red and yellow fibres) was greater at the site 
without incision (right) than within the healing incision (left). 
Notes: Picrosirius red, polarized light. Magnification × 100, scale bar 200 µm. 
Abbreviations: PCL, poly--caprolactone; TRS, thrombocyte-rich solution. 
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From histological point of view, both types of scaffolds (PCL and PCL+TRS) were 
well and uniformly integrated within the collagenous connective tissue of the healing 
incision. The most convincing finding was that the presence of both PCL nanofiber and 
PCL nanofiber + TRS scaffolds led to increased amount of contractile myofibroblasts 
within the healing incision, but the amount of microvessels in samples with scaffolds 
was comparable with samples without scaffolds. In PCL scaffold, the microvessel 
density was positively correlated with the fraction of type I collagen.  
We found no differences when comparing the PCL vs. PCL+TRS scaffolds. No 
differences were found in any of the parameters when comparing samples after 6 
weeks of healing vs. 12 weeks of healing.  
Tissue samples without any scaffold had more type I collagen after 12 weeks 
than samples with PCL+TRS. However, the mechanical properties of the abdominal 
wall and the differences caused by the amount of type I collagen and contractile 
myofibroblasts should be tested using biomechanics. The total thickness of the 
abdominal wall varied considerably and it exceeded the size of histological tissue 
samples in some cases.   
4.3.2.2 Quantitative histological results - grouping according to the scaffold 
type  
The quantitative histological results grouped according to the type of the scaffold 
are presented in Figure 35. Results in Figure 35A evaluated by ANOVA showed 
considerable differences among the groups in the area fraction occupied by α-smooth 
muscle actin-positive cells at the site of incision. The area fraction occupied by α-
smooth muscle actin-positive cells was greater in samples with PCL nanofibers and 
PCL nanofibers + TRS compared to samples treated with suture alone. Statistical 
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analysis of the result using the Mann Whitney U test showed a greater fraction 
occupied by α-smooth muscle actin-positive cells at the site of incision in samples with 
PCL nanofibres when compared with samples with no scaffold at 6 weeks (Figure 35B). 
The same statistical method showed also a greater fraction occupied by α-smooth 
muscle actin-positive cells at the site of incision in samples with PCL nanofibres + TRS 
when compared with samples with no scaffold when the samples from the 6 and 12 












Figure 35. The quantitative histological results grouped according to the type of the scaffold. (A) 
Considerable differences among the groups in the area fraction occupied by α-smooth muscle actin-
positive cells at the site of incision. (B) Greater fraction occupied by α-smooth muscle actin-positive 
cells at the site of incision in samples with PCL nanofibres when compared with samples with no 
scaffold at 6 weeks.  (C) Greater fraction occupied by α-smooth muscle actin-positive cells at the site 
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of incision in samples with PCL nanofibres + TRS when compared with samples with no scaffold (the 
samples 6+12 weeks pooled) 
Notes: (B) p=0.035. (C) p=0.015. 
Abbreviations: PCL, poly--caprolactone; TRS, thrombocyte-rich solution; Aa, area fraction. 
4.3.2.3 Quantitative histological results - grouping according to the healing time 
No differences were found in any of the parameters when comparing samples 
after 6 weeks of healing vs. 12 weeks of healing. For the statistical evaluation the Mann 
Whitney U test was used.  
4.4 In vitro testing of the scaffold base on cryogrinded PCL 
nanofibers with potential use as a drug delivery system 
for tissue engineering 
4.4.1 Cell adhesion on the microsphere system 
To evaluate the potential of prepared new drug delivery systems for tissue 
engineering, mouse 3T3 fibroblasts were seeded on microparticles and cell adhesion 
was analyzed after one day by confocal microscopy. Cell membranes were stained by 
DiOC6 and propidium iodide was used as a counterstain for cell nuclei. Results of 
confocal microscopy showed adhesion of cells to all three samples. Particles grinded 
in mannitol (Figure 36A) and 2-octanol (Figure 36B) showed good cell adhesion. 
Biocompatibility of particles ground in 2-octanol is quite surprising and could be 
explained by 2-octanol washing out during the sterilization of particles in ethanol. 









Figure 36. Adhesion of 3T3 fibroblasts on microparicles. (A) Microparticles cryogrinded in 10% 
mannitol. (B) Microparticles cryogrinded in 2-octanol. (C) Microparticles cryogrinded in 10% Pluronic 
F-68.  
Notes: Cell membranes are stained green with DiOC6 and nucleus red with propidium iodide. 
Morphology of microparticles is visualized with passing through light. Scale bar 100 µm. 
4.4.2 Proliferation and metabolic activity of the cells cultivated on the 
microsphere system 
In order to examine the cell proliferation and metabolic activity of 3T3 fibroblasts 
on PCL microparticles, 21‐day cultivation testing was performed. Cells were directly 
seeded on PCL microspheres cryogrinded in mannitol and ungrinded PCL mesh was 
used as a control. Quantification of DNA concentration in samples was measured on 
days 1, 7,14 and 21 by PicoGreen® assay (Figure 37). Results showed similar cell 
adhesion on day 1 on microspheres and nanofibers. Interestingly cell proliferation on 
days 7 and 14 was higher on microspheres. This result could be caused by higher free 
surface of microparticles. On day 21 the number of cells on microspheres decreased 
due to metabolic deprivation. On other hand, the number of cells on nanofibers 












Figure 37. Proliferation of 3T3 fibroblast cultivated on either PCL nanofibers or PCL microspheres. 
Microspheres were cryogrinded in 10% mannitol. 
Abbreviations: PCL, poly--caprolactone; ng, nanograms. 
Metabolic activity of cells was measured by MTS assay (Figure 38). Cells on 
microspheres showed higher activity on day 7 which is in agreement with results of 
PicoGreen® assay. Interestingly, metabolic activity on microspheres was lower 
compared to nanofibers on days 14 and 21. This result could be explained by higher 







Figure 38. Metabolic activity of 3T3 fibroblast cultivated on either PCL nanofibers or PCL 
microspheres. Microspheres were cryogrinded in 10% mannitol. 
Abbreviations: PCL, poly--caprolactone; AU, absorbance units. 
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In general, porous microspheres produced by cryogenic grinding are suitable for 
the cultivation of cells. They could serve as a scaffolding system and even adherent 
cells could be cultured in suspensions. Proliferation rate and metabolic activity was 
higher on the first 7 cultivation days and peaked on day 14. This result could be 
explained by the higher shear stress on microspheres and depletion of nutrients. 
Interestingly, standard deviation of microsphere samples was higher due to the size 
diversity of the system. Thus microsphere–cell interaction should be further examined 


















Incisional hernia is the most common postoperative complication following 
abdominal surgery, affecting up to 20% of patients after midline incision (Sugerman 
H.J. et al., 1996; Hoer J. et al., 2002). Insertion of a synthetic material has become the 
standard for care in abdominal wall hernia repair. More than a hundred surgical 
meshes have been developed by now, still there is no ideal mesh among those yet 
(Shankaran V. et al., 2011). The aim of the present study was to develop a composite 
functionalized nanofiber scaffold for preventing or repairing incisional hernias and in 
vitro testing of the new microsphere system with potential use as a drug delivery 
system in tissue engineering.  
Polypropylene is the most widely-used prosthetic material for repairing abdominal 
wall hernia (Cobb W.S. et al., 2009). A combination of PCL nanofibers with a 
polypropylene surgical mesh (Prolene™) was chosen as a suitable material for our 
studies. Nowadays, PCL seems to be used more often as a biocompatible soft and 
hard tissue material, and it also includes a resorbable suture, a drug delivery system 
and bone graft substitutes, but only few studies have investigated PCL for abdominal 
wall hernia repairs (Kweon H. et al., 2003; Williams J.M. et al., 2005). Guillaume et al. 
used PCL as a coating agent and a drug reservoir for anti-infective drugs by heating 
deposition onto polypropylene prostheses (Guillaume O. et al., 2011). Another study 
using PCL in the form of nanofibers as a carrier for antibiotics was evaluated by Bolgen 
et al. (Bolgen N. et al., 2007). The antibiotic embedded PCL membranes eliminated 
post-surgery adhesions and improved healing in rats. In the most recent study, Zhao 
et al used an electrospun PCL/collagen hybrid scaffold for congenital diaphragmatic 
hernia reconstruction in rats. The aligned scaffolds allowed muscle cell migration and 
tissue formation (Zhao W. et al., 2013). 
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In general, nanofibers have recently been used in various tissue engineering 
applications (Ma Z. et al., 2005a). An advantage of using nanofibers for hernia 
regeneration lies in the simplicity of the process for preparing submicron-scale fibers, 
and their low cost. In addition, manufactured nanofibers can easily be modified and 
functionalized to refine their biological and biomechanical properties. Various studies 
have proved that nanofibers, namely PCL nanofibers, support the adhesion, growth 
and proliferation of fibroblasts, chondrocytes and MSCs (Jakubova R. et al., 2011; 
Chen M. et al., 2007; Rampichova M. et al., 2013).  
In the first part of the present study, we have tested a new composite scaffold 
based on a PP surgical mesh, PCL nanofibers and adhered platelets. We have 
evaluated the effect of released natural GFs from platelets and the effect of PCL 
nanofiber functionalization on 3T3 fibroblast proliferation in vitro. In extensive tests, we 
have proved that PCL nanofibers have excellent biocompatible properties. We have 
confirmed that PCL nanofibers deposited on a PP mesh promote better adhesion, 
growth, metabolic activity, proliferation and viability of 3T3 fibroblasts in all tests than 
a PP mesh alone.  
The second part of the study has proven the suitability of a composite scaffold 
based on PCL nanofibers deposited on a PP mesh for hernia regeneration in a rabbit 
model. A histological and biomechanical evaluation revealed better healing capacity of 
PCL nanofibers than of a conventional PP mesh for preventing hernia formation. PCL 
nanofibers as novel absorbable scaffolds for hernia repair application were 
biomechanically tested by Ebersole et al. (Ebersole G.C. et al., 2012). The authors 
have shown that electrospun PCL scaffolds retain suture material and possess tensile 
strength appropriate for hernia repair, and therefore have the potential to be a novel 
class of hernia repair materials. Our scaffold combined good biocompatible properties, 
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environment-promoting cell growth, adherence due to the PCL nanofibers, and tensile 
strength due to the PP mesh. This part of the study has confirmed that adhesion of 
various synthetic growth factors on the surface of our nanofibers increased their 
regenerative potential. GF such as bFGF, IGF-I and TGF-2 may stimulate 
angiogenesis, fibroblast proliferation and collagen synthesis, thus enhancing tissue 
stability (Hant T.K. et al., 1984; Mustoe T.A. et al., 1987; Yaeger P.C. et al., 1997). 
Their concentration ratio and their positive effect on cultivated cells were evaluated in 
our group by Filova et al. (Filova E. et al., 2008).  
The groups of Ebersole et al. and Deeken et al. measured the tensile strength 
and other biomechanical parameters of the prosthetic material used in ventral 
(incisional) hernia repair without implantation into animal models or human patients 
(Ebersole G.C. et al., 2012; Deeken C.R. et al., 2011). These studies showed that the 
tensile strength of PCL nanofibers was appropriate for most hernia repairs. 
Electrospun scaffolds possessing mechanical properties within the predefined range 
may be suitable for further evaluation in preclinical trials (Deeken C.R. et al., 2011). In 
another study, Melman et al biomechanically tested samples implanted into a porcine 
model (Melman N. et al., 2011). Samples were attached into the tension meter 
branches over the entire thickness of the abdominal wall including the prosthetic 
material.  We suggest a new biomechanical testing method, where the results reflect 
the real state the repaired abdominal wall. In our design the attachment points were 
adjacent to the implanted mesh, so we tested not only the strength of the implant but 
also the properties of mesh-fascia interface and its resistance to distracting forces. We 
did not test the tensile strength of our samples alone, because the biomechanical 
parameters of PP meshes are well known (Melman N. et al., 2011). We modified this 
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prosthetic PP material with PCL nanofibers, thus it was not necessary to evaluate the 
biomechanical parameters before implantation.  
Biomechanical testing 6 weeks post implantation in the rabbit model showed that 
the PCL nanofibers improved the biomechanical properties of the healed tissue, as 
evidenced by a higher average maximal strength force. This applies not only to the 
nanofibers in combination with a PP mesh, but also to the suture alone. The group 
treated with suture and PCL nanofibers with or without adhered synthetic GFs showed 
a modulus of elasticity comparable with that of the PP mesh, but higher average 
maximal strength force. This could reflect lower fibroblast proliferation around the PP 
mesh, which might be caused by a reduction in the mechanical signals that arise as 
the structural soft tissue fails (Franz M.G., 2006). In addition to these results, video 
analysis of the biomechanical testing of the samples from in vivo study on rabbits 
revealed in most cases that if the tissue tore first between the edge of the mesh and 
healthy tissue, the PP mesh slid off the surface of the muscle. In samples 
functionalized with PCL nanofibers, we observed two types of tear mechanism. Some 
were like in the PP mesh group, but in other samples the slide was localized between 
muscle fibers. When the PCL nanofibers were used, different types of tear were 
observed. In some samples, the suture line tore first, whereas in others a tear occurred 
between muscle fibers or at the edge of the muscle and the PCL nanofibers. This 
indicates that PCL nanofibers provide support for fusion of fascia without causing a 
significant increase in local stiffness, or the formation of a major tension concentrator, 
as in the case of a PP mesh. Finally, as we had expected, the suture line broke first if 
it was not supported by any mesh. 
The third part of the present study proved the suitability of a nanofiber scaffold 
based on PCL nanofibers and PCL nanofibers with adhered platelets for hernia 
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regeneration in a minipig model. Both scaffold types were well and uniformly integrated 
within the collagenous connective tissue of the healing incision. In adition, the 
presence of both PCL nanofiber and PCL nanofiber + TRS scaffolds led to increased 
amount of contractile myofibroblasts within the healing incision. In PCL nanofiber 
scaffold, the microvessel density was positively correlated with the fraction of type I 
collagen. On the other hand, unfortunately, we did not observe any differences in any 
assessed parameters in the samples after 6 weeks of healing compared to samples 
after 12 weeks of healing. We also did not observe increase of any parameters with 
using PCL nanofibers functionalised with adhered platelets. Probably the concentration 
of the platelets in the TRS at the level of five times physiological concentration was not 
sufficient to cause any changes.  
The quality of the ECM deposition is dependent among others on the content of 
collagen, which influenced the mechanical properties of the tissue and is notably 
influenced by the kind of mesh material (Junge K. et al., 2002). In the all examined 
samples either in rabbit study or in minipig study, there were no significant differences 
among the groups in the area fraction of total collagen.  However, the analysis of the 
main tissue constituents, i.e., the collagen fraction, the adipose tissue fraction, and 
leukocyte infiltration suggested that the presence of either a simple suture or a PP 
mesh resulted in the formation of a scar with a greater adipose tissue fraction (Figure 
31 and 32). Tissue samples with heavier granulomatous infiltration also contained 
more blood vessels and a higher fraction of vascular smooth muscle and 
myofibroblasts. This finding supports the hypothesis mentioned above that there is 
lower fibroblast proliferation (Franz M.G., 2006). Simple sutures contained a large 
amount of collagen. This supports the hypothesis of tissue flexibility, but these samples 
also contained a decreased amount of -smooth muscle actin positive cells. There 
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were more actin positive cells in both the medial and the lateral parts of samples 
containing PCL nanofibers than in the other groups. In in vivo tests on rabbit model, 
the samples with a PP mesh functionalized with PCL nanofibers with adhered GFs 
included also more -smooth muscle actin positive cells in a part distant from the 
incision. This could be explained by chemotaxis in this area. In both in vivo studies we 
have proven that nanofibers are a good substrate for cell attachment, and thus they 
promote cell proliferation and ECM synthesis.  
Advanced improvement of our composite scaffolds seems to be promising for 
regenerating ventral or incisional hernias. We used a simple drug delivery system 
developed in our group, based on either platelets or synthetic GFs adhered onto PCL 
nanofibers (Jakubova R. et al., 2011). The approaches that have been used so far, in 
which simple GFs or platelets are administered, may tend to diffuse active substances 
away from the site of the injury (Tabata I.I., 2000). The problem of refusing of active 
substances can be solved by using suitable biocompatible scaffolds, to which the 
desired drugs could be attached. One of the first attempts to set up a dual drug delivery 
system based on polymeric scaffolds was reported by Richardson et al (Richardson 
T.P. et al., 2001). Better control of either drug or GF pharmacokinetics could be 
achieved by using a combination of active substances with natural or synthetic 
biomaterials, such as collagen or PCL composite scaffolds (Rai B. et al., 2005). 
Previous studies have mentioned various drug delivery systems based on a PCL 
composite scaffold successfully used for hernia regeneration (Guillaume O. et al., 
2011; Bolgen N. et al., 2007).  
In the last part of our study we demonstrated that the PCL microspheres prepared 
by cryogrinding is a promising system potentially exploitable as a drug delivery system 
in tissue engineering. In general, porous PCL microspheres produced by cryogenic 
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grinding are suitable for cell cultivation. We have proved it by using metabolic activity, 
adhesion and proliferation assay. 
PCL nanofibers were used in all parts of our study as a carrier or a potential 
carrier of GFs gradually released either from platelets adhered on the nanofiber 
surface or directly from nanofibers, with the aim of using the material in hernia 
regeneration. The use of this system enabled us to avoid the complications caused by 
a burst release of high doses of GFs. In addition, the GFs are prevented from 
proteolysis and loss in bioactivity both by the scaffold and by the platelets themselves 
(Babensee J.E. et al., 2000). This enables a prolonged therapeutic effect of GFs. GFs 
naturally occurring in platelets have been shown to be effective in promoting wound 
healing and regeneration (Nauta A. et al., 2011). Platelets in the form of TRS or PRP 
have been playing a rapidly growing role in tissue engineering (Tonti G.A. et al, 2008.). 
The positive effect of PRP on fibroblast proliferation has already been described by 
Anitua et al, Creeper et al and Passaretti et al. (Anitua E. et al., 2009; Creeper F. and 
Ivanovski S., 2012; Passaretti F. et al., 2014). Unfortunately these teams did not use 
a polymeric scaffold, so it was not possible to observe the benefits from the 
multiplication of the positive effect on the fibroblasts from both the polymer scaffold 
and the PRP. Platelets were shown to release numerous growth factors with mitogenic 
and anabolic function (e.g. PDGF, EGF, TGF-β; Plachokova A.S. et al., 2008; 
Nikolidakis D. and Jansen J.A. 2012). Our observation of increased proliferation, 
metabolic activity and DNA synthesis of the 3T3 fibroblasts in TRS containing samples 
groups in the present study is explained by stimulatory effect of such active molecules. 
In addition platelets upon activation form protein layer consist of fibrinogen, von 
Willebrand factor (VWF) and other proteins (Blair P. and Flaumenhaft R., 2009), which 
together with the PCL nanofibers mimicking ECM has a possible stimulatory effect on 
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cell adhesion. Moreover, we used in our study TRS which does not include leukocytes 
and erythrocytes in comparison to PRP obtained from whole blood. Prosecka et al 
showed that even human TRS promote tissue regeneration in rabbit model with a 
minimal immunological negative response (Prosecka E. et al., 2014). That kind of 


















In the present study, we have confirmed the biocompatibility of PCL nanofibers 
with adhered platelets in the form of TRS deposited on a PP mesh. This composite 
scaffold provided better adhesion, growth, metabolic activity, proliferation and viability 
of 3T3 fibroblasts in all tests than on a PP mesh alone, and even better than on a PP 
mesh functionalised by PCL nanofibers. The gradual release of growth factors from 
biocompatible scaffolds is a promising approach in tissue engineering and 
regenerative medicine.  
Our experiments have also proved that the composite scaffolds based on 
polypropylene surgical mesh functionalized with PCL nanofibers and adhered synthetic 
growth factors positively affected the fascia healing in a rabbit model. Thanks to their 
nanofiber structure, PCL nanofibers provide a better environment for cell growth and 
proliferation, either in combination with a PP mesh or alone, and are therefore are a 
suitable alternative to a standard hernia mesh. Surprisingly, scaffolds with no PP mesh 
showed even better fascia healing and higher elasticity than a widely-used surgical 
mesh. PCL nanofiber scaffolds are promising materials for use in hernia repair. By 
adhering GF into their structure we can further improve several parameters, especially 
in the quantity of collagen that is produced compared to the adipose tissue content.  
In vivo tests on minipig model have proved, that the composite scaffolds based 
on either PCL nanofibers or PCL nanofibers functionalised with adhered human 
platelets obtained from TRS improved tissue healing. Scaffolds well integrated into the 
collagenous connective tissue of the healing incision and using of them led to 
increased amount of contractile myofibroblast at the site of incision. 
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The last system tested in the present study has proven its potential use as a drug 
delivery system in tissue engineering. The microsphere system based on cryogrinded 
PCL nanofibers has supported cell adhesion and proliferation. In the future a big 
potential of this system lies in the possibility of replacement of simple PCL nanofibers 
with either coaxial nanofibers with PCL as a shell part or with PCL nanofibers prepared 
by emulsion electrospinning with using active substances incorporation. Cryogrinded 
microspheres are a suitable and promising scaffolding system for use in tissue 
















Incisional hernia is the most common postoperative complication which affects 
up to 20% of patients after abdominal surgery. Insertion of a synthetic surgical mesh 
has become the standard for care in abdominal wall hernia repair. However, 
implementation of a mesh does not reduce the risk of recurrence and the onset of 
hernia recurrence is only delayed by 2-3 years. Nowadays, more than one hundred 
surgical meshes are available on the market from which the polypropylene is most 
widely used for abdominal wall hernia repair. Nonetheless, the ideal mesh does not 
exist yet - it still needs to be developed. The aim of the present study was to develop 
a functionalized scaffold for abdominal wall hernia regeneration and in vitro testing of 
the new microsphere system with potential use as a drug delivery system in tissue 
engineering. We prepared novel composite scaffolds based on a polypropylene 
surgical mesh functionalized with polycaprolactone nanofibers and adhered either 
platelet as a natural source of growth factors or a synthetic growth factor. In extensive 
in vitro tests, we have proven the biocompatibility of polycaprolactone nanofibers with 
adhered platelets on a polypropylene mesh. A histological and biomechanical 
evaluation from in vivo tests revealed better healing capacity of our composite 
functionalized scaffolds in comparison with either a conventional polypropylene 
surgical mesh or a simple suture for preventing hernia formation. The microsphere 
system based on cryogrinded PCL nanofibers has proven its potential to be used as a 
drug delivery system in biomedical application. The gradual release of growth factors 
from biocompatible nanofiber-modified scaffolds seems to be a promising approach in 





Incizionální kýla postihuje víc než 20% pacientů, kteří podstoupili operaci břicha. 
Implantace syntetických materiálů se stala standardem v reparaci kýl břišní stěny. 
Nicméně implantace kýlních sítěk nezaručuje trvalé zhojení, jen oddaluje riziko recidivy 
vzniku kýly o 2-3 roky.  V současnosti je na trhu dostupná víc jak stovka chirurgických 
sítěk. Nejčastěji používané síťky pro reparaci ventrální kýly jsou vyrobené z 
polypropylénu. Ideální síťka dodnes neexistuje a je tudíž zapotřebí ji vyvinout. Cílem 
této studie bylo vyvinout funkcionalizovaný nosič pro reparaci kýl břišní stěny. Připravili 
jsme nový kompozitní nosič na bázi polypropylénové chirurgické síťky 
funkcionalizovaný pomocí poly--kaprolaktonových nanovláken připravených 
elektrostatickým zvlákňováním. Na nanovlákna byly adherovány buď trombocyty, jako 
přirozený zdroj růstových faktorů, nebo syntetické růstové faktory. V rozsáhlých in vitro 
testech jsme jednoznačně prokázali biokompatibilitu tohoto nového systému. 
Histologické a biomechanické hodnocení v in vivo testech na modelu králíka a 
miniprasete odhalilo lepší regenerační schopnost našeho kompozitního 
funkcionalizovaného nosiče ve srovnání s konvenčně používanou polypropylénovou 
chirurgickou síti a samotnou suturou. Dále byl testován systém mikročástic vyrobený 
pomocí kryomletí poly--kaprolaktonových nanovláken sloužící jako systém dodávání 
léčiv v biomedicínských aplikacích. Postupné uvolňování růstových faktorů 
z biokompatibilních nanovlákenných nosičů, se jeví jako slibný přistup v tkáňovém 
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